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Abstract
The implantation of biomaterials in the body leads to a reaction known as the foreign body
response (FBR) which leads to the eventual encapsulation of the biomaterial. This encapsulation proves
to be detrimental to certain biomaterials, such as implanted glucose sensors, which rely on interacting
with the extracellular space for proper function. Altering the FBR has become of interest in an effort to
increase the longevity and integration of biomaterials. One strategy for altering the FBR is by targeting
the macrophage, shown to play an important role in the FBR. In this work, the microdialysis sampling
technique was used to deliver modulators to an implant site in an effort to alter the predominant
macrophage activation state present. Simultaneously, analytes were collected from the same implant site
to further characterize the biochemical signals present during the FBR as well as in a predominantly M2c
environment. With the use of 100kDa molecular weight cut-off microdialysis membranes, it was first
necessary to find a suitable perfusion fluid to use for this work which did not cause additional
inflammation. An acceptable perfusion fluid was found to consist of Ringer’s + 4% w/v Dextran-500 +
0.1% w/v BSA. Further, it was found that Dexamethasone-21-phosphate (Dex), when delivered
immediately through the microdialysis probe, resulted in a significant increase in M2c macrophages found
in the tissue surrounding the treatment. Immediate Dex administration also resulted in the significant
down-regulation of CCL2 and IL-6 transcripts as well as significantly decreased CCL2 concentrations
found in treatment dialysates. The delayed infusion of Dex was also investigated to determine if a
different/more optimal effect was seen as compared to an immediate administration. The delayed
administration of Dex resulted in a significant increase in the number of M2c macrophages in the tissue
surrounding the treatment probe. Interestingly, at the transcription level, delayed Dex resulted in a
significant up-regulation of IL-6. Further, CCL2 concentrations were reduced in treatment dialysates but
in a pattern different from what was seen in response to immediate Dex administration. This work shows
that modulators can be used to alter the macrophage activation state at a non-degradable implant site.
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Chapter 1

Introduction
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Implanted biomaterials have become common place in today's society with many people having
prosthetic joints (artificial knees, hips), screws holding bones together, dental implants, and pacemakers.
A common phenomenon with implanted biomaterials is the body's immune response to the foreign
material known as the foreign body response (FBR) [1-4]. This response leads to the eventual
encapsulation of the material. While this response does not affect the performance of many biomaterials,
such as the ones named above, it can be detrimental to other biomaterials. Implanted glucose sensors
rely on interacting with the extracellular fluid (ECF) to make measurements. In the case of implanted
glucose sensors, the FBR leads to outputs which do not reflect the body's glucose level but rather the
glucose level found within the microenvironment of the encapsulation surrounding the implant. Due to
these detrimental effects, understanding the FBR is a field of interest with hopes to better integrate
biomaterials into host tissue.
Macrophages are cells in the body which have been shown to exist in many forms and play an
essential role in the integration of a biomaterial. The study of the different phenotypes of macrophages at
the implant site, and the dominance of certain types of macrophages at the implant site is thought to
result in improved outcomes in relation to biomaterials [5]. For this reason, inducing certain macrophage
activation states at an implant site may be beneficial. While different materials have been used to elicit a
desired macrophage activation state, it is unknown whether modulators can be used to shift the
macrophage activation state at a non-degradable implant site. Further, the molecular properties which
are associated with different activation states are incompletely understood, in vivo.
This work is the first to use modulators to attempt regulating the macrophage activation state at a
non-degradable implant site. The primary hypothesis is that by producing a predominantly M2c activation
state, improved healing will be seen at an implant site. It was the aim of this work to determine the
efficacy of different modulators to shift macrophages to a predominantly M2c activation state at a
microdialysis probe implant site, as well as characterize the molecular response. Through these studies
a multitude of discoveries were made. First, when using microdialysis sampling, Dextran-70 should be
avoided as it can lead to inflammation at the implant site as well as tissue necrosis. However, Dextran500 can be used as a safe alternative to Dextran-70. Dexamethasone-21-phosphate (Dex) can be
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delivered through the microdialysis probe to alter the activation state of macrophages. The delivery of
Dex results in an increase in the percentage of M2c macrophages seen in the tissue surrounding the
microdialysis probe. Interestingly, differences were seen when Dex was delivered immediately following
probe implantation as compared to a delayed delivery. In tissue where Dex was immediately delivered,
fewer macrophages were seen as compared to delayed delivery. The gene expression profiles also
differed. While both CCL2 and IL-6 were significantly down-regulated in the tissue from immediate Dex
delivery, IL-6 was seen to be significantly up-regulated in response to a delayed Dex infusion. Finally,
CCL2 protein concentrations were decreased in the dialysate in response to both immediate and delayed
Dex infusions. However, a decrease is seen much sooner in response to immediate Dex infusion as
compared to delayed infusion with the response in the delayed infusion being more transient. These
results show that it is possible to use modulators to shift macrophages in vivo to a desired activation state
at a non-degradable implant site while also further characterizing a predominantly M2c environment.

Macrophage Activation

Monocytes are the largest of the leukocytes (white blood cells) with an ameoboid shape and
kidney bean shaped nucleus. These cells are known to play a role in innate immunity. Innate immunity is
the body's first line of defense to microbes or any foreign invading molecule. This is a non-specific
response consisting of epithelial cells (physical barrier), phagocytic cells (e.g. macrophages which ingest
and destroy invading material), natural killer cells (cells which will kill microbe infected cells), the
complement system (which promotes the phagocytosis of microbes as well as attracts neutrophils, a
white blood cell), and cytokines (signaling proteins which mediate inflammation and immune responses)
[6]. One of the roles monocytes are known to play is to replenish resident macrophages. Inflammatory
monocytes are known to be recruited to a wound site where they are differentiated to macrophages [7].
Macrophages are known to have multiple morphologies, from round, to pancake shaped, to elongated [8],
and are characterized as having large nuclei with noticeable lysosomes. These cells are known to be
much larger than monocytes with human macrophages measuring ~20 microns.
3

Macrophages have long been recognized as scavenger cells due to their ability to phagocytose,
or engulf, cellular debris and dead cells. These cells also play a role in innate immune responses by
phagocytosing pathogens. This process is facilitated by the expression of pattern recognition receptors
(PRR) being present on the cell surface of macrophages. PRRs do not recognize any one specific
molecule but rather recognize a pattern. These PRRs are able to identify an array of molecules known as
pathogen-associated molecular patterns (PAMPs) such as bacterially-derived carbohydrates
(lipopolysaccharide (LPS) or mannose) found on gram negative bacteria, peptidoglycans found on gram
positive bacteria, nucleic acids such as bacterial or viral DNA or RNA, glucans from fungi, and
lipoproteins [9-11]. The recognition of one or more PAMPs, by a PRR found on the cell surface of a
macrophage, results in the phagocytosis of the pathogen. Once the pathogen has been phagocytosed, it
is destroyed due to an oxidative burst within the macrophage. For this reason, resident macrophages are
found throughout the body in areas likely to encounter pathogens, i.e., the skin, lungs, and liver.
Macrophages are also known to play a role in adaptive immunity, or acquired immunity because
people are not born with it but develop it over time. Adaptive immunity is called into action in response to
an innate immune response, the non-specific recognition of microbes due to conserved molecular
patterns [11]. Adaptive immunity differs from innate immunity in that adaptive immunity is a highly
specific response to a particular antigen and is characterized as producing long-lived protection against
the antigen [12]. Adaptive immunity is carried out via antibody responses where B cells are activated to
produce antibodies specific for the antigen which mounted the response or by cell mediated responses
where T cells kill infected cells or release signaling molecules which activate macrophages to destroy
microbes which have been phagocytosed [12].
While the ability of macrophages to phagocytose cellular debris, dead cells, and pathogens, as
well as their role as antigen presenting cells has long been recognized, more recently different states of
macrophages have been shown to exist. The different states of macrophages have been coined as
polarization states. In 2000, Mills et al. coined these polarization states as being M1 and M2 [13]. The
two prominent macrophage polarization states are M1, or classically-activated macrophages, and M2, or
alternatively activated macrophages [14] with the polarization state present depending on the cues
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present in the microenvironment [15-17] (Figure 1). At this point it should be noted that this classification
of macrophages is somewhat simplified in that the classification represents the two extremes of a
continuum in which macrophage populations will exist [15]. Further, it should be recognized that these
cells have been shown to be plastic, switching from an M1 to M2 state and vice versa in vitro by altering
the cytokines present in the culture media [18, 19] as well as reverting to their initial state after the
removal of the stimulus [20]. More recently, it has been suggested that 'polarization states' should be
avoided for the use of 'activation states' and that instead of using the M1/M2 nomenclature, the modulator
which was used to create the macrophage should be stated, e.g. M (LPS) for a macrophage which was
created in response to LPS treatment [21]. For this document, the M1/M2 nomenclature will be used as a
generalization to describe cells which have been elicited in response to one of the many modulators
which may result in an M1 or M2 macrophage while the M (modulator) will be used to describe specific
macrophages or macrophages elicited in this work.
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Fig. 1. Image showing the different polarization states of macrophages. The phenotype of macrophage present
depends on the inducers which are present in the microenvironment. These different phenotypes are
characterized by the cell surface markers they express as well as differential expression of cytokines and genes.
Abbreviations: DTH=Delayed type hypersensitivity, IC=immune complex, MR=mannose receptor, PTX3=the long
pentraxin, RNI=reactive nitrogen intermediates, SRs=scavenger receptors
Reprinted from Trends in Immunology. 25/12 Mantovani, Alberto et al. The chemokine system in diverse forms of
macrophage activation and polarization. 2004 with permission from Elsevier.
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M1 macrophages are considered to be pro-inflammatory macrophages. These cells are
responsible for eliciting a Th1 type response due to a bacterial infection. These cells are induced by LPS,
interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α). As discussed earlier, LPS is a
bacterial carbohydrate found on the cell walls of gram negative bacteria. IFN-γ is a pro-inflammatory
cytokine produced primarily by Th1 cells and is thought to 'prime' macrophages making them more
responsive to LPS challenge [22, 23]. TNF-α is a pro-inflammatory cytokine produced primarily by
macrophages in response to activation of toll like receptor (TLR) 4, a specific type of PRR found on the
cell surface of macrophages, by LPS [24-27]. The M1 response to biomaterials is generally accepted as
a low grade response where M1 macrophages are seen in the early stages of wound healing and then
transition to M2 macrophages [28]. In fact, the low grade response has recently been shown in a rat
model where collagen discs were implanted subcutaneously [29]. However, the severity of the M1
response has been shown to depend on a multitude of different factors. In a recent study, a mouse
model was used to show that higher numbers of M1 macrophages were seen in response to increased
acetylation of a chitosan scaffold [30]. Further, Badylak's group has shown that surgical meshes which
are cross-linked, the chemical joining of two molecules via a covalent bond, result in a larger M1
response than those which are not [31, 32]. Also those which contain a cellular component result in a
larger M1 response [33] in rats.
M1 macrophages are characterized as being highly phagocytic and bactericidal [14, 34]. These
cells are characterized as producing high amounts of pro-inflammatory cytokines such as Interleukin (IL)
1β, IL-6, IL-12, IL-15, IL-18, IL-23, and TNF-α, [14, 35]. These cells are also known to secrete
chemokines CCL15, CCL20, CXCL9, CXCL10, CXCL11, and CXCL13 [14] as well as reactive oxygen
intermediates [36, 37]. M1 macrophages also show increased amounts of the receptor CCR7 (C-C
Chemokine Receptor type 7) [35, 38] (which binds both CCL19 and CCL21 [39] and is responsible for the
homing of immune cells to secondary lymphoid organs [39, 40]), MHC II (which plays a role in the
presentation of extracellular proteins [41]) [18, 37, 42], CD80 (a molecule known to be a co-stimulator for
T cell activation [6]), and CD64 (a cell surface receptor able to bind monomeric IgG with high affinity [43]
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resulting in activated macrophages [6]) [44]. Further, M1 macrophages are capable of converting Larginine to nitric oxide via inducible nitric oxide (iNOS). It should be noted at this point that while
increased iNOS production has been seen in M1 macrophages from murine models [45], iNOS
production from human macrophages has proven to be far less reliable with iNOS not being detected in
human macrophages in vitro but detected in human tissue samples [45-48]. It has been argued, by
Murray and Wynn, that this may be due to culture media missing components needed for the production
of iNOS by human macrophages [49]. In this work, the gene expression levels of iNOS have been
utilized as an indicator of macrophage activation state.
M2 macrophages are a broad category of macrophages which are considered to be activated in
response to stimuli other than what has been stated for M1 macrophages, e.g. in response to apoptotic or
necrotic cells, or material which is too large to be phagocytosed. For this reason, these macrophages
have been dubbed as alternatively-activated macrophages. However, unlike the M1 class of
macrophages which currently consists of no subclasses, the M2 class can be further subdivided into three
subclasses: M2a, M2b, and M2c. Each of these subclasses have unique characteristics and are elicited
by different stimuli. With this said, M2 macrophages as a whole have been characterized as being antiinflammatory in nature and in fact have been shown to be an indicator of biologic scaffold outcome where
predominantly M2 wound sites result in improved healing and integration as compared to wound sites
which are predominantly M1 [31]. It is important to note at this point that wound sites typically express a
combination of M1 and M2 macrophages.
M2 macrophages are shown to increase arginase activity, resulting in arginine being converted to
ornithine and urea [50] resulting in reduced iNOS production [51]. M2 macrophages show an increased
expression in the cell surface receptor, CD206 (Cluster of Differentiation 206), previously called the
macrophage mannose receptor, mannose receptor C type 1. This receptor was one of the first to be
used to identify M2 macrophages, primarily macrophages induced by IL-4/IL-13 [(M(IL-4/IL-13)]. It has
recently been shown, in human monocytes collected from buffy coats and then differentiated to M2
macrophages using macrophage colony stimulating factor (M-CSF), that CD206 can be used as a nonspecific M2 marker instead of an M2a marker [52] with expression levels of CD206 being shown to
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significantly increase in response to M-CSF, dexamethasone (Dex), transforming growth factor beta
(TGF-β), and IL-4 in human macrophages [52].
For many years, inducing macrophages with IL-4/IL-13 was said to produce an M2 macrophage.
It now is recognized that the use of IL-4/IL-13 to induce macrophages elicits an M2a response [14, 35,
53]. M2a macrophages are described as eliciting a Th2 type response, type II inflammation, and playing
a role in the encapsulation and killing of parasites and helminths [15, 35] as well as in allergic responses
[35, 44] but do not present antigen to T cells in vitro [15]. These cells produce anti-inflammatory
cytokines IL-1ra, IL-4, and IL-10 as well as suppressing the production of pro-inflammatory cytokines
such as IL-1β, IL-6, IL-12, and TNF-α [14, 35]. Further, it has been shown that IL-4 plays a role in the
fusion of macrophages to form foreign body giant cells (FBGC), though other factors, such as cell density,
cell source, time of exposure to IL-4, and type of adherent substrate, may play a role in the effectiveness
of IL-4 to produce FBGCs [2, 54-58]. The ability of IL-4 to promote FBGC formation may help explain the
role these macrophages play in response to parasites, helminths, and biomaterials.
At the cell surface, M2a macrophages are characterized as expressing increased amounts of
MHC II along with CD206 [59]. The expression of CD206 is important in that it can be used to help
distinguish these cells from M1 macrophages as CD206 is decreased in response to IFN-γ, a common
M1 inducer [60]. Further, in human macrophages, CD209 (previously recognized as DC-SIGN) has been
shown to be specifically up-regulated in response to IL-4 [38, 52] whereas Ambarus et al. found that
CD200R was specifically up-regulated by IL-4 and not IFN-γ or IL-10 [44] making it a possible M2a
marker. CD209 is a C-type lectin, a carbohydrate binding protein, which was originally identified as a
specific marker for dendritic cells [61] but has been shown to be expressed by macrophages [62, 63].
CD209 is known to bind viruses, fungi, bacteria, and mycobacteria, and [61, 64, 65], parasites [63] as well
as aid in immunosuppression by different pathogens, including HIV, to evade immune surveillance [63,
66].
M2b macrophages are quite possibly the least characterized M2 activation state of macrophages.
M2b macrophages differ from M2a macrophages in many ways, primarily by the fact that these
macrophages produce pro-inflammatory cytokines while M2a macrophages do not. M2b macrophages
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are induced by the ligation of immune complexes (e.g. Fc or complement) [67], TLRs [35], and IL-1
receptor [35]. These cells produce pro-inflammatory cytokines such as IL-1, IL-6, TNF-α [35, 67], and
CCL1 [68, 69] as well as producing nitric oxide more abundantly than arginase, similar to M1
macrophages [67, 70]. However, like M2 macrophages, these cells produce little to no IL-12 but high
amounts of IL-10 (an anti-inflammatory cytokine) [35, 67, 70]. M2b macrophages are identified by their
expression of LIGHT (Tumor Necrosis Factor superfamily 14) and SPHK1 (sphingosine kinase 1) genes
[68, 70, 71] as well as MHC II on the cell surface [35]. These macrophages are known to play a role in
the remission of lupus, promote Leishmania infection, suppress pro-inflammatory responses, and are
induced by the pro-inflammatory clearance of apoptotic neutrophils [67].
The final subset of M2 macrophages are the M2c macrophages, currently recognized by their
expression of CD163 (to be discussed later) at the cell surface. M2c macrophages are induced by IL-10,
glucocorticoids, and TGF-β [14, 16, 35]. Like other M2 macrophages, M2c macrophages are
characterized as being anti-inflammatory and suppressing the production of pro-inflammatory cytokines
such as IL-1β, IL-6, IL-8, IL-12, and TNF-α [14]. The anti-inflammatory nature of M2c macrophages is
further developed by the production of the IL-1 decoy receptor IL-RII, IL-10, and TGF-β [14, 35]. M2c
macrophages are similar to M2a macrophages in that they metabolize L-arginine to ornithine resulting in
an increase in arginase and a decrease in iNOS.
At the cell surface, M2c macrophages are known to have decreased expression of MHC II
making them poor antigen presenting cells. However, M2c macrophages have an increased expression
of scavenger receptors on their cell surface which alludes to their role as tissue remodeling cells.
Immunohistochemically, these cells have been identified by their cell surface expression of CD163 which
was recently shown to be specific to M2c cells [44, 52]. CD163 is a scavenger receptor which is a
member of the scavenger receptor cysteine-rich group B family [72]. Kristiansen et al. originally identified
CD163 as being a scavenger receptor responsible for the Ca

2+

dependent endocytosis of hemoglobin-

haptoglobin (Hb-Hp) complexes [73]. They showed that CD163 only binds the Hb-Hp complex, preferably
the 2-2 Hb-Hp complex, and not free Hb [73]. As the implantation of a biomaterial results in rupturing of
blood vessels, hemoglobin is released which will bind haptoglobin. CD163 is thought to play an anti-
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inflammatory role by binding the Hb-Hp complex, endocytosing the complex, and converting the Hb to
anti-inflammatory metabolites bilirubin and carbon monoxide [74, 75].
Recently, human macrophages, differentiated from monocytes collected from blood donors,
which were treated with either IL-10 in conjunction with macrophage colony stimulating factor (M-CSF)
[M(IL-10+M-CSF) macrophages] or dexamethasone alone [M(Dex) macrophages] have been shown to
express Mer tyrosine kinase (MerTK) on their cell surface resulting in the clearance of early apoptotic
cells [52]. MerTK is a protein which recognizes unmodified phosphotidylserine, an apoptotic marker,
resulting in the engulfment of the apoptotic cell by macrophages [52]. The clearance of apoptotic cells is
important to proper wound healing as late apoptotic cells become necrotic, resulting in a pro-inflammatory
clearance of these cells [52, 76, 77]. Table 1 shows a breakdown of the different activation states of
macrophages as well as their characteristics.
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Table 1. Activation States of Macrophages as Well as Their Characteristics.
Pro-/Anti-inflammatory
Inducers

Cytokines/Chemokines
secreted

Arginine Metabolism
Cell Surface Markers

Physiological role

M1
ProIFN-γ, LPS,
TNF-α

M2a
AntiIL-4, IL-13

IL-1β, IL-6, IL12, IL-15, IL-18,
IL-23, TNF-α,
CCL15, CCL20,
CXCL9,
CXCL10,
CXCL11,
CXCL13 [14, 35]
Produce iNOS
CCR7, CD64,
CD68, CD80,
MHC II [18, 35,
37, 38, 42, 44]
Produce Th1
response to
bacterial
infection.

IL-1ra, IL-4, IL10. Suppress IL1β, IL-6, IL-12,
TNF-α [14,35]

Produce arginase
CD68, CD200R,
CD206, CD209
(Humans), MHC
II [38, 51, 53, 44]
Produce Th2 type
response, type II
inflammation,
play a role in
encapsulation
and killing of
parasites and
helminths
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M2b
Ambiguous
Ligation of
immune
complexes (Fc or
complement),
Toll-Like
Receptors, IL-1
receptor
CCL1, IL-1, IL-6,
IL-10, TNF-α [35,
66-69]

M2c
AntiDexamethasone,
IL-10, TGF-β

Primarily iNOS
CD68, MHC II
[35]

Produce arginase
CD68, CD163,
MerTK (Human)
[44, 53]

Play a role in the
remission of
lupus, promote
Leishmania
infection,
suppress proinflammatory
response

Scavenge
hemoglobinhaptoglobin
complexes,
clearance of
apoptotic cells,
matrix deposition,
tissue remodeling

IL-1 receptor
decoy IL-RII, IL10, TGF-β.
Suppress IL-1β,
IL-6, IL-8, IL-12,
TNF-α [14, 35]

The M2c macrophage state has become of interest, especially in the field of biomaterials, due to
its being an anti-inflammatory, pro-wound healing, pro-tissue remodeling cell [17, 35]. Due to these
characteristics of the M2c macrophage, it is hopeful that eliciting a predominantly M2c environment
around an implant will result in better integration of the implant with the tissue and improved outcomes.
To this point, the field has focused on the use of different materials-based approaches to elicit a
predominantly M2 environment around an implant. This approach has garnered a better understanding of
the relationship that exists between biomaterial constituents and macrophage activation state. However,
this work is the first to look at an M2c response around a non-degradable biomaterial.
In a study where mesh scaffolds were implanted in rats, it was shown that implants which had
been chemically cross-linked elicited a predominantly M1 response whereas non cross-linked scaffolds
elicited a predominantly M2c response [32]. The cellularity of scaffolds has also been shown to affect
macrophage activation state with scaffolds having a cellular component eliciting a predominantly M1 state
while de-cellularized scaffolds, whether allogeneic (from the same species) or xenogeneic (from different
species), elicit a predominantly M2c state [33]. Further, it has been shown that the predominantly M2c
environment surrounding these implants results in improved integration and outcome with less fibrosis
and scarring and more vessel formation as compared to the M1 predominant environment [33]. While the
previous work was done using degradable biomaterials, it does suggest a means for studying other
biomaterials. The work shows that if the environment surrounding a biomaterial consists predominantly of
M2c macrophages, improved integration and outcome are achieved.
Previous studies have been performed in which drug releasing biomaterials where used to
modulate the FBR. Many modulators including basic fibroblast growth factor, bone morphogenetic
protein, CCL2, dexamethasone, icaritin, IL-10 gene, mastinib, platelet derived growth factor, TGF-β1,
TGF-β2, and vascular endothelial growth factor [78-93] have been used in drug eluting biomaterials.
However, other than the recent work by Boehler et al., these studies have relied on histology to determine
the effectiveness of their modulator and none have looked at immunohistochemistry to determine the
predominant macrophage phenotype present in the tissue surrounding the implant. Further, these drug
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releasing biomaterials suffer from initial burst of modulator followed by a continuous slow release which
cannot be controlled. The work presented in this dissertation is the first to utilize a non-degradable
implant to deliver modulators to a wound site in an attempt to shift the activation state of macrophages
(outlined in Table 2). The non-degradable implant utilized is a microdialysis probe which prevents the
initial burst of modulators seen in other drug releasing biomaterials and allows for the controlled release
of the modulator over time. If a two pronged approach is used where modulators successful at shifting
macrophages to the desired activation state are found, followed by investigation as to the optimal time
point to administer those modulators, this could open the door for increased longevity of biomaterials
such as implanted glucose sensors by allowing better integration of the biomaterial into the host tissue.
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Table 2. Different Strategies Utilized to Shift Macrophage Activation State
Unknown
Ability of proven in vitro
modulators to shift
macrophage activation state in
vivo.

Effect of modulator on protein
conc.

Effect of modulator on gene
expression.

Strategy
Perfused IL-10 and Dex through
microdialysis probe and looked at
activation state of macrophages
in the tissue surrounding both
control and treatment tissue via
IHC. (CD68 and CD163 for both
modulators, and CCR7 and
CD206 for IL-10)
Measured CCL2 conc. in
dialysate from both control and
treatment probes.

Studied regulation of multiple
genes via qRT-PCR. (Arg2,
CCL2, CD163, CD206, IL-1ra, IL6, IL-10, Lipo-1, iNOS2, TGF-β1,
TNF-α)

Effect of an immediate delivery
of modulator as compared to a
delayed delivery on
macrophage activation state.

Dex delivered immediately
following microdialysis probe
implantation as well as 3 days
post implantation.

Effect of modulator on tissue
histology.

Tissue surrounding the
microdialysis probe subjected to
hematoxylin and eosin and
Masson's Trichrome stains.

Result
IL-10 had minimal effects on the
+
amount of CD163 macrophages.
Dex resulted in a significant
increase in the percentage of
+
+
M2c (CD68 CD163 )
macrophages.
IL-10 had no significant effect on
CCL2 concentration.
Dex significantly decreased the
concentration of CCL2 collected
in the dialysate.
Dex significantly down-regulated
CCL2 and IL-6 when
administered immediately
following probe implantation.
Dex significantly up-regulated IL6 when administered 3 days post
implantation.
The percent of M2c
macrophages present were
similar in the immediate and
delayed infusion Dex studies.
However, more macrophages
were seen in the tissue from the
delayed Dex infusion study.
IL-10 resulted in undesirable
effects (ring of blood, cellular
debris) immediately surrounding
the treatment probe but reduced
cellularity and collagen further
away.
Immediate Dex infusion resulted
in mostly unusable treatment
tissue sections with those that
were obtained showing
decreased cellularity but no
difference in collagen.
Delayed Dex infusion resulted in
increased cellularity in treatment
tissue but no appreciable
differences in collagen.
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Foreign Body Response

Park and Lakes defined a biomaterial as “A synthetic material used to replace part of a living
system or to function in intimate contact with living tissue” [94]. The use of biomaterials, e.g. prostheses,
biosensors, breast implants, heart valves, pacemakers, in recent decades have increased to the point
where it is not uncommon to know someone with a biomaterial implant. Given the extremely common
nature of these implants, it has become of great interest to understand how the body reacts to these
implants and reduce the amount of inflammation and rejection, with the highest rates seen in hip
replacements at 40%, due to these implants. Materials which enter the body and are > 10 µm in size
cannot be phagocytosed [2]. In the case that an object cannot be phagocytosed and is recognized as a
foreign material, the body has a specific way of dealing with the object. The FBR is the body’s response
to any recognized implanted material, helminth, or foreign material which is too large to be phagocytosed
(Figure 2). For this work we will focus on biomaterials which are> 10 µm in size.
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Fig. 2: Image showing the steps involved in the foreign body response. The foreign body response is the body’s
response to a biomaterial or material which enters the body and is too large to be phagocytosed. Reprinted from
Surface Science.,500, Castner, D.G., Ratner, B. D. Biomedical surface science: Foundations to frontiers 2002, 2860 with permission from Elsevier.
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The response is initiated by the implantation of the biomaterial. During the implantation process,
mechanical injuries occur to the tissue which include the destruction of cells and blood vessel severing,
resulting in the initiation of the inflammatory response, thrombus activation, the activation of the
complement system, and platelets [2]. Immediately following the implantation of the biomaterial, a layer
of proteins, including fibrinogen, fibronectin, vitronectin, IgG, von Willebrand factor, and others,
spontaneously adsorbs to the surface of the biomaterial [95]. This deposition of proteins on the surface of
the biomaterial is known as the formation of a provisional matrix [1]. The provisional matrix is a
biodegradable substance which contains an array of biological substances such as chemoattractants,
cytokines, and growth factors.
The perturbation of the tissue sets into effect acute inflammation. Acute inflammation is
inflammation which lasts minutes to days depending on the amount of injury with resolution generally
occurring within one week. Following the adsorption of proteins to the biomaterial surface, cells arrive at
the implant to investigate the biomaterial. This response happens within hours of the biomaterial being
implanted. Initially, acute inflammation is characterized by the wound site being predominated by
neutrophils [1, 2]. These neutrophils migrate, via capillaries, to the implant site where they extravasate to
the tissue surrounding the implant. The primary role of these neutrophils is to phagocytose any foreign
material including microorganisms. Due to its size, the neutrophil is unable to phagocytose the
biomaterial. While phagocytosing does not occur, the neutrophils release enzymes to degrade the
biomaterial through extrusion or exocytosis [96, 97]. Neutrophils immigrate to the wound site for a short
amount of time and are short lived cells which die after about 24-48 hrs. It is generally accepted that the
wound site will be predominated by neutrophils for ~ 3 days [1]. Three to five days post-implantation, a
shift in the cell type which predominates the wound site occurs with macrophages becoming predominant.
The leukocytes, first the neutrophils then the macrophages/monocytes, are drawn to the wound
site in response to the chemokine gradient, a chemical ligand gradient, which exists causing cells to move
to an area of high chemokine concentration [98]. The chemokine gradient is established when
chemokines are secreted in response to different cytokines and bind to glycosaminoglycans which
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preserve higher concentrations of chemokines at the site of inflammation [99]. Chemokines are
responsible for the recruitment of leukocytes, e.g. monocytes, neutrophils, lymphocytes, to a wound site.
Chemokines are a subset of cytokines, which can be subdivided into four families: C, CC, CXC, CX3C
with the X representing the number of amino acids separating the conserved cysteine residues at the Nterminal [100, 101].
Different members of the chemokine families are responsible for the recruitment of specific cell
types to a wound site. The neutrophils are recruited to the wound site in response to CXCL8 [IL-8
(KC/GRO in rats and mice] and to some extent TNF-α [102] while CCL2 (MCP-1) has been shown to be
the primary chemokine responsible for the migration of monocytes to a wound site [103]. Further, CCL2
has been shown to be present in the exudate macrophages collected from high molecular weight
polyethylene implants placed in the subcutaneous space [104]. However, it has been argued that CCL2
is not imperative for the recruitment of monocytes to subcutaneous biomaterial implants but rather plays a
role in FBGC formation [105]. It should be noted though that these experiments were carried out using
different biomaterials as well as different species. In the case where CCL2 was seen to not be imperative
for monocyte recruitment, the experiments were carried out in CCL2 null mice and it is not unreasonable
to think that more than one chemokine is capable of recruiting monocytes to a wound site in the case
where one chemokine is unavailable.
Once the macrophages arrive at the wound site, they are attracted to the provisional matrix which
has formed around the biomaterial. This 'attraction' is a result of integrin binding motifs which are found
on the surface of biomaterials. Integrins are adhesion molecules which allow the movement of cells
through the ECF allowing the cell to respond to its environment [106]. Macrophages are known to
express three different classes of integrins: β1, β2, β3. These integrins recognize integrin binding motifs
found in proteins which compose the provisional matrix thereby allowing macrophages to bind. While the
primary binding event of macrophages to the provisional matrix is yet to be elucidated, it has been
suggested that multiple proteins may play a role. Early in vivo studies, by Tang and Eaton using a mouse
model, showed that animals with low levels of fibrinogen were unable to mount a response to the
biomaterial unless the material was coated with fibrinogen or fibrinogen was injected into the animal, thus
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concluding that fibrinogen was the primary protein needed for adhesion [107]. In vitro studies by
Anderson's group have shown that macrophages/monocytes will initially adhere via β2 integrins which
bind to various proteins, e.g. fibrinogen, complement, fibronectin, and IgG [108, 109]. These β2 integrins
have also been associated with podosome formation in macrophages [110, 111]. A podosome is a
protrusion of the plasma membrane which represents attachment sites for cells to the extracellular matrix
[112] and has been identified as the major adhesive structure in macrophages in vitro [1]. The formation
of these podosomes allows for the spreading of the macrophages over the surface of the biomaterial.
Once macrophages have adhered and spread over the surface of the biomaterial, a process
which can be described as interrogating the biomaterial, the macrophages will fuse together to form
foreign body giant cells. The formation of these FBGCs occurs in response to the size disparity that
exists between the biomaterial and the macrophage and the inability of the biomaterial to be
phagocytosed. The formation of these FBGCs around implants have been seen in many different models
including but not limited to, a rat model where polyether-polyurethane sponge discs were implanted
subcutaneously [113], a rat model where multiple different scaffolds were implanted subcutaneously
[114], where nitrocellulose is injected in the foot pads of mice [115], around both polyetherurethane and
polyethylene terephthalate implanted subcutaneously in mice [116], as well as in my own work where
microdialysis probes were implanted subcutaneously for 14 days in rats.
Many different factors have been identified with the extent to which FBGCs form around a
biomaterial. Anderson's group has done much work in this area and has shown that IL-4 can be used to
induce FBGC formation in vitro with IL-13 being shown to be an equally potent inducer of FBGCs [55,
117]. Further, their group was able to show that IL-4 is an important factor in the formation of FBGCs in
vivo [54]. While the mechanism behind this FBGC induction is unclear, it may be in part due to the fact
that both IL-4 and IL-13 significantly up-regulate CD206 which is thought to play a role in the fusion
process as this receptor is localized at areas of the cell where fusion is occurring [2]. Further, in a mouse
model where polyethylene terephthalate disks were implanted in the subcutaneous space, it was found
that plasma fibronectin (pFN) played a role in the formation of FBGCs with results showing three times as
many FBGCs in pFN knockout mice as compared to controls [118].
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The formation of these FBGCs results in a microenvironment which exists between the FBGCs
and the biomaterial. While the biomaterial is unable to be phagocytosed, a process known as 'frustrated
phagocytosis' occurs. Frustrated phagocytosis is a term which was coined by Henson in which
macrophages and FBGCs are capable of releasing degradative substances, e.g. reactive oxygen
intermediates, phagosomes, oxygen free radicals, and enzymes, into the area between these cells and
the biomaterial [96]. This puts the surface of the biomaterial in direct contact with high concentrations of
these substances, and low pH (phagosome can have a pH as low as 4 [119]) which may destroy some
materials, such as polyethylene and polypropylene, resulting in failure of the device.
FBGCs not only release degradative substances at the implant site but also release cytokines, in
fact it has been shown that FBGCs release IL-1α and TNF-α at four weeks post nitrocellulose injections in
mice [115]. This suggests that FBGCs may play a role in prolonging the inflammatory response. In a
mouse model, it was shown that the release of TGF-β1 coincided with the predominance of FBGCs in
response to nitrocellulose injections at 45 and 60 days post injection [115]. This might suggest that
FBGCs play a role in the formation of a fibrotic capsule. Also it is known that IL-4/IL-13 play a role in the
formation of FBGCs. The presence of IL-4/IL-13 as well as the release of TGF-β by FBGCs may play a
role in the activation and recruitment of fibroblasts to the implant site [120]. The activated fibroblasts will
become myofibroblasts as they migrate toward the implant [120]. The myofibroblasts are responsible for
the production of collagen. The myofibroblasts and collagen production initially promote the closing of a
wound. The correct balance of collagen production and degradation result in the wound healing without
the formation of scar tissue. However, in the case of biomaterials, an acellular fibrotic capsule is created
around the biomaterial resulting in the biomaterial being in its own microenvironment separate from the
body. The formation of this fibrotic encapsulation is due in part to the rate of collagen being produced
exceeding the rate at which the ECM (Extracellular Matrix) is degraded [120]. The formation of this
encapsulation proves to be detrimental to some biomaterials, e.g. biosensors, which require interaction
with the body for proper function. For this reason, it would be of great interest to alter the formation of the
fibrotic encapsulation around biomaterials.

21

In an effort to further understand and reduce the formation of the fibrotic encapsulation as well as
improve integration, many researchers have investigated different materials as well as different
chemistries. Through these works many aspects that play a role in the size of the fibrotic encapsulation
have been discovered. Biomaterials that are constructed with porous materials show a decreased FBR
and fibrotic capsule size as well as an increase in the amount of vascularity [121-124]. Brauker et al. was
the first to show this effect on fibrosis and vascularity [125]. However, there is debate as to the optimal
pore size. In a series of experiments, Sharkawy et al. showed that a 60 µm pore size was superior to no
pores, 5 µm, and 700 µm pores resulting in increased diffusivity, increased vascularization, and optimal
response times to changes seen in the plasma [121-123]. The Ratner group showed that a pore size of
34 µm was superior to no pores and pores of 160 µm [124, 126]. While the 34 and 60 µm pores have
never been compared directly, it might be assumed that the response would be similar as they are of the
same relative size. These studies support the use of a microdialysis probe as a model due to the porosity
of the membrane. While the pores of the membrane are much smaller than those in the above studies,
the pores should still result in improved healing, as compared to a non-porous material, as well as allow
the delivery of modulators. Unfortunately, no studies have been performed to determine the activation
state of macrophages surrounding a non-degradable implant. Instead, conclusions on the predominant
macrophage activation state surrounding an implant must be drawn from degradable implants.
Badylak's group has investigated the cross-linking and cellular component of implanted scaffolds.
They have found that non-cross-linked scaffolds degrade in less time than do cross-linked scaffolds,
produce an M2 vs M1 response, and avoid the chronic inflammation associated with cross-linked
scaffolds [32, 127]. In another study, Badylak's group found that scaffolds with a cellular component,
whether autologous (from the same animal) or xenogeneic, resulted in a predominantly M1 macrophage
response and dense collagen deposition and scarring [33]. Further, acellular scaffolds were shown to
produce a predominantly M2 macrophage response and resulted in improved healing containing more
vascularization, no scarring, and islands of skeletal myoblasts [33]. These findings are important in that
they show the macrophage phenotype can be altered in vivo, and show improved healing is seen when a
predominantly M2 response is established. However, it must be considered that a degradable biomaterial
was utilized. In the case of non-degradable implants, cellularity, cross-linking, and porosity may be fixed
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aspects of the biomaterial, as is the case for the microdialysis probe. For this reason, alternative
methods to changing the material itself must be investigated. The use of modulators at an implant site
might allow for the shift of macrophage activation state to a predominantly M2c state resulting in improved
tissue integration leading to increased longevity of some biomaterials.

Microdialysis Sampling Technique

Microdialysis sampling technique is a minimally-invasive, widely used, in vivo sampling technique
for monitoring bioactive molecules. Any technique is designated as being invasive if the skin is broken or
a body cavity is entered. Non-invasive techniques are those which do not break the skin such as X-rays
while invasive techniques, such as open heart surgery, allow the doctor to fully see the surgical site.
Minimally-invasive techniques, are any techniques which are less invasive than open surgery with subdermal implants being included in this category.
Microdialysis sampling technique was originally designed on the premise that the microdialysis
probe works by mimicking a blood vessel in vivo [128]. The microdialysis probe consists of inlet tubing,
inner cannula, semi-permeable membrane (with a defined molecular weight cut-off (MWCO)), and outlet
tubing. This device is capable of being implanted in almost any tissue type and has been used in multiple
different types. During sampling procedures an isotonic fluid with physiological pH is passed through the
inlet, down the inner cannula, between the outside of the inner cannula and the semi-permeable
membrane, and out the outlet tubing (Fig 3). This allows microdialysis sampling technique to be used to
collect molecules found in the extracellular fluid (ECF) which can then be quantified.
Microdialysis sampling works based on diffusion wherein the concentration gradient that exists
between molecules found in the ECF and the perfusion fluid inside the probe, results in molecules smaller
than the MWCO crossing the probe membrane and being collected in the dialysate [129]. Likewise, this
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concentration gradient allows for molecules at a higher concentration inside the microdialysis probe to
cross the membrane and be delivered to the ECF.
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Fig. 3: Image showing a microdialysis probe and schematic of how it works. Adapted
from Chapter 3 Figure 1. Reprinted from European Journal of Pharmaceutical Sciences,
57 , Geoffrey D. Keeler, Jeannine M. Durdik, Julie A. Stenken, Comparison of
microdialysis sampling perfusion fluid components on the foreign body reaction in rat
subcutaneous tissue, Pages 60-67, Copyright (2013), with permission from Elsevier
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Given that the perfusate is continuously moving through the microdialysis probe, the length of the
membrane is defined, and the flow rate is sufficiently high to collect enough dialysate for analysis while
maintaining temporal resolution (~1 µL/min), collection of analytes does not happen at an equilibrium
state. For this work, equilibrium state is defined as the concentration of a given analyte being the same
inside the probe as it is outside the probe, meaning the amount of analyte entering the probe is equal to
the amount of analyte concentration in the tissue surrounding the probe. Instead, the amount of analyte
recovered via microdialysis sampling technique is a fraction of the analyte present in the ECF [130].
The efficiency at which an analyte crosses the microdialysis probe membrane and is collected is
known as the extraction efficiency of that molecule. The extraction efficiency (EE) of an analyte is
generally given as a percentage and is defined as shown below in Equation 1, where Cinlet is the
concentration of the analyte in the

(1)

probe, Coutlet is the concentration of the analyte leaving the probe, and C∞ is the concentration of the
analyte far away from the probe. One common way to increase the EE is to lower the flow rate. Lower
flow rates have been shown to increase the EE [131, 132]. However, while a lower flow rate has been
shown to increase EE, 60 µL of sample are needed to perform an ELISA, greatly restricting the lowest
flow rate which can be used while maintaining temporal resolution. Thus, a compromise must be struck
between the flow rate and the amount of sample needed. For much of the work presented in this
document, a flow rate of 1 µL/min was used as this was seen to meet this compromise.
Another characteristic of microdialysis sampling which must be considered is the difference in
concentration of a modulator in the probe as compared to far away from the probe. That is, only a
percentage of the modulator which is perfused through the probe will actually cross the membrane and
enter the ECF. Further, as the modulator enters the ECF it will diffuse, resulting in higher concentrations
close to the probe with concentrations dropping further away from the probe.
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Since its inception, microdialysis sampling technique has gained popularity for a multitude of
reasons. The technique is considered to be a minimally-invasive technique which allows for the
collection/monitoring of molecules at a given wound/trauma site in awake and freely-moving animals as
well as humans. This is an important advantage over many other techniques such as biopsies, which are
capable of sampling tissue at a wound site but are considered to be highly invasive, or blood draws which
are considered to be minimally invasive but are not indicative of what is happening at the wound site,
rather in the periphery.
The microdialysis sampling technique is also capable of taking continuous samples post
implantation at a given wound site via one implantation procedure. This characteristic has three main
advantages, 1) increased temporal resolution per wound is gained as compared to other techniques such
as suction blisters or biopsies, 2) reduced numbers of wounds, 3) reduced animal numbers for a study.
At this point it should be mentioned that while multiple samples can be collected from one microdialysis
probe, increasing temporal resolution per wound, these samples are an average of the molecular
concentrations collected over a sampling period. Microdialysis sampling technique is also unique in that
the same probe can be used to simultaneously collect molecules from the ECF while delivering
modulators to the ECF. This allows for the near real-time view of the effects different modulators may
have on a wound site. Furthermore, given that multiple probes can be implanted into a single animal, one
can be used to deliver a modulator while one does not, allowing each animal to serve as its own control
thereby greatly reducing the number of animals needed for a given study. Finally, the samples collected
from microdialysis sampling technique are considered to be analytically-clean. This means that samples
require little to no sample preparation before being analyzed allowing for a multitude of chemical analyses
to be used [133].
Initially, this technique was used to collect small, hydrophilic compounds such as glucose,
pyruvate, and catecholamines. Probes used for this type of work consisted of small MWCO membranes,
usually 20 kDa or less. For this type of collection, balanced salt solutions, such as Ringer's (an isotonic,
physiologically pH matched solution), were often used as these contained the same ions at the same
strength as were found in the ECF [134] and resulted in no loss of fluid across the membrane. With the
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advent of high MWCO (100 kDa) membranes it became possible to collect larger molecules such as
cytokines as well as other proteins [135]. Further, with the advent of commercially available high MWCO
membranes this type of sampling gained popularity as it gave a means to investigate a multitude of
disease states where cytokine levels may be dysregulated [136-144]. However, when a salt solution
alone, such as Ringer's, is used as a perfusion fluid in high MWCO membranes, an undesirable side
effect is seen, fluid loss or ultrafiltration.
Ultrafiltration is problematic in that it results in decreased fluid recoveries making quantification
techniques with volume requirements, i.e. ELISA, difficult to perform. Furthermore, the physiological
effects of the fluid leaving the probe and collecting in the ECF are poorly understood. While poorly
understood, it could be speculated that the fluid loss would lead to edema at the probe implant site which
could lead to the dilution of molecules resulting in concentrations which are not indicative of a typical
trauma site. In an effort to combat this problem different osmotic reagents were added to the perfusion
fluid shifting the osmotic balance in a manner which prevents ultrafiltration. While different osmotic
agents have been used, the two most commonly used are Dextrans and bovine serum albumin (BSA) or
a combination of the two [145-147]. While dextran-60 and dextran-70 were osmotic agents of choice for
decades, it has recently been shown that these dextrans are able to diffuse across the microdialysis
membrane and enter the ECF resulting in inflammation [144]. The diffusion of dextrans across a 100 kDa
MWCO membrane has further been shown by Chu et al. who showed that both Dextran-40 and Dextran250 are capable of diffusing across a 100 kDa membrane, in vitro [148]. While BSA was shown to cause
no increased inflammation at the wound site, it was shown to be needed at high concentrations, >10%
w/v, to appreciably reduce ultrafiltration [144]. However, Dextran-500 was shown to result in no
increased inflammation at the wound site while giving 100% fluid recovery in vitro [149] and in this work
acceptable fluid recovery in vivo have been observed when Dextran-500 was used at 4-6% w/v.
While the use of Dextran-500 successfully eliminates the problem of ultrafiltration, it does nothing
to solve the second issue which plagues the collection of proteins, non-specific binding of proteins to the
inner walls of the tubing during collections. To circumvent this problem, BSA is commonly included in
perfusion fluids at low concentrations, i.e. 0.1% w/v, to reduce non-specific binding of collected proteins.

28

BSA is an acceptable additive to perfusion fluids, at least in a rat model, as it shows no appreciable
increase in inflammation surrounding a microdialysis probe as compared to rat serum albumin. Given the
non-inflammatory effects of BSA as well as being inexpensive and commercially available, it is an
appropriate choice as a blocking agent for microdialysis tubing.
Given the characteristics of microdialysis sampling technique, it is a valuable tool for the
investigation of the molecular mechanisms occurring at a wound site and shows great promise for the
investigation of the FBR. It can be used to deliver modulators to a wound site, while monitoring the
biochemical processes which are occurring. For these reasons, it was used in this work as a model
system for studying macrophage activation at a non-degradable implant site. More specifically, the
technique was used to determine if modulators could be used to shift the activation state of macrophages
at a non-degradable implant site to a predominantly M2c state while monitoring the effects on protein
levels, gene transcription, and tissue histology.
The work in this dissertation focused on whether proven in vitro modulators can be used to shift
macrophages to an M2c state in vivo. To determine if this was possible, modulators (IL-10 and Dex) were
delivered to an implant site and immunohistochemistry was used to determine the predominant
macrophage activation state present. Many different strategies were utilized to fully elucidate the effects
of IL-10 on macrophage activation state, in vivo with minimal success (Appendix A). What was found was
that IL-10 had a minimal effect on the presence of M2c macrophages in the tissue surrounding a
microdialysis probe. However, Dex (when administered immediately following implantation) significantly
increased the number of M2c cells in the tissue surrounding the probe while also altering gene
transcription and protein levels. Further, this work looked at whether a delayed Dex infusion might be
more beneficial than an immediate infusion. To determine this, Dex was not infused until three days post
implantation of the microdialysis probe. This type of infusion resulted in significantly more M2c
macrophages in the tissue surrounding the treatment probe as compared to the control probe while
altering gene transcription as well as protein levels in a manner different than was seen in response to
immediate Dex infusion. This work has shown that a modulator can be delivered via a non-degradable
biomaterial to successfully shift macrophages in the tissue to an M2c activation state. While this work is
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exciting and the first of its kind, more is needed to fully understand how this shift in macrophage activation
will affect the integration of the biomaterial into the surrounding tissue.
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Materials and Methods
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Chemicals

The following chemicals were used in this study:Anti-CD68 Antibody (Santa Cruz Biotechnology,
Inc., Dallas, TX); Anti-CD163 Antibody (Santa Cruz Biotechnology, Inc., Dallas, TX); Apex

TM

Antibody

Labeling Kits (Alexa Fluor 488 and Alexa Fluor 647) (Life Technologies, Carlsbad, CA); BDOptEIA
IL-10 ELISA Set (BD Biosciences, San Jose, CA); BD OptEIA

TM

TM

Rat

Rat MCP-1 ELISA Set (BD Biosciences,

San Jose, CA); bovine serum albumin (BSA) (Rockland Immunochemicals, Gilbertsville, PA); Chloroform
(MP Biomedicals LLC, Solon, OH); Dexamethasone-21-phosphate disodium salt (Dex) (Sigma Aldrich, St
Louis, MO); Dextran-70 and Dextran-500 (Sigma Aldrich, St Louis, MO); Ethylene oxide (Anderson
Sterilizers, Inc, Haw River, NC); formalin, 10% and neutral buffered (BDH, VWR, West Chester, PA); Halt
Protease Inhibitor (Pierce, Rockford, IL); HPLC grade water (Fisher Scientific, Waltham, MA); isoflurane
®

(Abbott Laboratories, North Chicago, IL); Optimal Cutting Temperature solution (Sakura Finetek,
Torrance, CA); povidone-iodine (Professional Disposables International Inc, Orangeburge, NY);
Proteinase K (Qiagen, Venlo, Limburg); Rat Serum Albumin (RSA) (Sigma Aldrich, St Louis, MO);
Recombinant Interleukin-10 (R&D Systems, Minneapolis, MN); RNAlater (Life Technologies, Carlsbad,
CA); Trizol (Life Technologies, Carlsbad, CA); Taqman® Gene Expression Assays (Arg2, CCL2, CD163,
CD206, IL-1ra, IL-6, IL-10, iNOS2, Lipo-1, TGF-β1, Taf9b, and TNF-α) (Life Technologies, Carlsbad, CA);
Ringer’s solution contained 150 mM NaCl, 5.4 mM KCl, 2.3 mM CaCl2 (For all experiments up to
Perfusion Fluid Comparison, Chapter 3), and 147mM NaCl, 4.6mM KCl, 2.3 mM CaCl2 (For all
experiments after Perfusion Fluid Comparison, after Chapter 3) pH 7.4 and was prepared in HPLC-grade
water. All other chemicals were reagent-grade or higher.

Microdialysis Sampling

All microdialysis sampling procedures were performed using CMA 20 microdialysis probes with
polyethersulfone (PES) membranes, 100 kDa MWCO and 10 mm length (Harvard Apparatus, Holliston,
MA). Prior to implantation, microdialysis probes were sterilized using ethylene oxide (Anderson
Sterilizers, Inc, Haw River, NC). The probes are perfused using a BAS Bee pump with appropriate
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syringes (Bioanalytical Systems Inc., West Lafayette, IN). After completion of the surgical procedures to
1

implant the microdialysis probe, the animal was placed into a CMA 120 freely moving animal collection
1

system (CMA Microdialysis, Solna, Sweden ), except where otherwise stated.

Surgical Procedures

Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) in the weight range of 230-400
grams were used and were housed in a climate controlled room at 72°F. Prior to surgical procedures,
rats were allowed access to both food and water ad libitum. All animal experiments were approved by the
University of Arkansas Institutional Care and Use Committee (IACUC) and were in compliance with the
NIH standards for the ethical treatment of animals.
Rats were anesthetized in an induction chamber with 5% isoflurane in 0.8 L/min oxygen. The rat
was then maintained on a nose cone via 2.5% isoflurane in 0.4 L/min oxygen during probe implantation.
During the surgical procedure the body temperature was maintained using a CMA 150 temperature
controller (CMA Microdialysis, Solna, Sweden). Surgical procedures were performed using aseptic
technique. All surgical tools were autoclaved prior to use. The surgical site was shaved and then
swabbed with povidone-iodine prior to any incisions.
To implant the microdialysis probe, a '┴' shaped incision was made into the posterior dorsal
subcutaneous tissue followed by a '-' shaped incision made near the base of the neck. Both incisions
were about 0.5 cm in length. An autoclaved straw was then passed through the subcutaneous tissue
from the posterior to anterior incisions. The tubing lines of the microdialysis probe were then run from the
posterior to anterior end of the straw such that outlet lines were located on the anterior side of the rat.
The straw was then removed from the animal. A plastic introducer that has split tubing (Harvard
Apparatus, Holliston, MA) was then placed subcutaneously at the posterior incision site. The
microdialysis probe was then placed in the introducer and the introducer was removed by pulling the
tubing to the side and the fluid lines were pulled tight. The posterior incision was closed using Vetbond
(3M, St Paul, MN). A second microdialysis probe was then implanted on the opposite side of the spine
using the same procedure. The two probes were separated by at least 2.5 cm (Fig 1). Post collection,
1

CMA now owned by Harvard Apparatus
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the animal was placed under light anesthesia and the lines were placed under the skin at the anterior
incision in a subcutaneous pocket. The anterior incision was then closed using surgical staples and the
animal was returned to housing.
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Anterior
incision where
subcutaneous
pocket is made
to place lines.

Fig. 1. Image showing the placement of the microdialysis probes. Image
taken by author.

47

Comparison of microdialysis sampling perfusion fluid components on the foreign body reaction in
rat subcutaneous tissue

Perfusion Fluid Comparisons.

For all perfusion fluid comparisons, two probes were implanted into the rats. Three animals were
used in each set. Unless otherwise specified, perfusions through the probes were performed every day
for four days. At this point, the anterior incision with the pocket for tubing lines was closed using
TM

Vetbond . On the seventh day post implantation, the animals were euthanized via CO2 asphyxiation and
the probes, along with the tissue immediately surrounding the probe, were explanted by using scissors to
remove a ~1 inch by ~2 inch piece of tissue which contained the probe. A sterile scalpel was then used
to cut around the probe removing any excess tissue not in immediate contact with the probe. The tissue
containing the probe was then held in a fashion which allowed for a scalpel blade to be used to cut the
probe and its encapsulation tissue, which can be seen surrounding the probe (~ 1-2 mm), away from the
remaining tissue. The probe and tissue were then stored in 10% neutral buffered formalin.

Probe Only vs. Ringer's Solution Filled Probe.

One probe had no fluid passed through it while the other had Ringer's solution perfused through
at a flow rate of 3 µL/min until fluid was observed exiting the outlet tubing at which point the flow was
stopped. Fresh Ringer’s solution was infused through the implanted dialysis probe as described above
each day for four days, including the day of implantation. On the fourth day, the anterior incision was
permanently closed using Vetbond

TM

and the animals were returned to housing.
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Ringer's vs. Ringer's + Dextran-70

One probe was perfused using Ringer’s solution while the other was perfused using Ringer's
solution with 6% (w/v) Dextran-70. After implantation of the probes, the animals were moved to a CMA
120 freely moving bowl which allows for microdialysis sampling to be performed in awake and freelymoving animals. Upon placement of the animal in the freely-moving animal system, a flush (3 µL/min)
through the implanted probe was performed and reduced to 0.5 µL/min, in increments of 0.5 µL/min over
25 minutes. Infusions were then performed at 0.5 µL/min for 1 hour. At the end of the 1 hour infusion, a
flush (3 µL/min) was performed using filter sterilized HPLC grade water.

RSA vs. BSA.

The same procedure was followed as the Ringer's vs Ringer's with Dextran-70 except for the
following differences. One probe was perfused with Ringer's solution with 3% (w/v) BSA and the other
with 3% (w/v) Rat Serum Albumin (RSA). The 3% albumin solutions were necessary to prevent
ultrafiltration.

Dextran-500 vs. Dextran-500 + BSA.

The same procedure was followed as the Ringer's vs. Ringer's with Dextran-70 except for the
following differences. One probe was perfused with Ringer's solution containing 6% (w/v) Dextran-500
(Sigma Aldrich St Louis, MO) and the other was perfused with Ringer's solution plus 6% (w/v) Dextran500 and 0.1% (w/v) Bovine Serum Albumin (BSA).

Histological Analyses.

Tissue was fixed in 10% neutral buffered formalin. It was subsequently embedded in paraffin
blocks and cut using a microtome (~5 µm). The tissue sections were de-paraffinized, and then stained
using standard protocol for both hematoxylin and eosin (H&E) and Masson's Trichrome by Mr. David
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Cross with the USDA Histology Lab, University of Arkansas. Tissue sections were then analyzed using a
Zeiss Axioskop II plus microscope (Carl Zeiss Inc., Thornwood, NY) with Cannon EOS Digital Software
for Rebel T2i camera.

Localized Delivery of Dexamethasone-21-Phosphate via Microdialysis Implants in Rat Induces M2c
Macrophage Polarization and Alters CCL2 Concentrations

Collection Procedure

Two probes were implanted with one serving as the control and the other as the treatment. The
control perfusion fluid consisted of Ringer's + 0.1% BSA + 4% Dextran-500 while the treatment perfusion
fluid contained an added 20 µg/mL Dex. Dextran-500 was used as an osmotic agent [1] and BSA was
used to reduce non-specific binding [2, 3]. Prior to implantation, control and treatment probes were
flushed with Ringer's or Ringer's + 20 µg/mL Dex, respectively. Post probe implantation, animals were
moved to a CMA 120 freely moving animal system. An initial flush was then performed using the
perfusion fluids which started at 3 µL/min and was reduced to 1.0 µL/min in 0.5 µL/min increments over a
20 min period. Infusions were then performed in 1 hour increments for 6 hours. All collection vials
contained Halt Protease Inhibitor and were immediately placed in ice once collection was complete. A
th

final flush was performed following the 6 hour of collection for 30 mins at 3 µL/min using Ringer's or
Ringer's + 20 µg/mL Dex for the control and treatment, respectively. Following the flush, the animal was
anesthetized and the lines were placed in a subcutaneous pocket at the anterior (Fig 1) incision. The
animal was then returned to housing. This procedure was performed every day for 3 days. At the end of
rd

the 3 day the animal was euthanized and the probes and tissue surrounding the probes were harvested
as previously stated [4]. The tissue was either removed from the probe and stored in RNAlater for PCR
studies or the probe and the tissue surrounding it were placed in optimal cutting temperature (OCT)
solution and flash frozen using liquid nitrogen for immunohistochemical studies.
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qRT-PCR Procedure

Tissue was harvested from around the membrane portion of the microdialysis probe and placed
o

in RNAlater and stored on ice. Once all tissue was harvested, it was moved to 4 C where it was stored
until RNA was extracted. RNA was extracted using the Trizol method and was purified using an RNeasy
Minikit (Qiagen, Venlo, Limburg) per the manufacturer's instructions. Prior to conversion of RNA to
cDNA, the integrity of the RNA was checked by running samples on a gel and looking at the 18s and 28s
bands (Fig 2). RNA was then converted to cDNA using a high capacity cDNA reverse transcription kit
(Life Technologies, Carlsbad, CA), per the manufacturer's instructions. Taqman gene expression assays
(Life Technologies, Carlsbad, CA) were then used to determine the relative gene expression ratios via a
7500 Real Time PCR Instrument (Life Technologies, Carlsbad, CA). Data were analyzed using REST
Gene Quantification Software [5] (http://rest.gene-quantification.info/).
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Fig. 2. Image showing non-degraded 28S and 18S bands from RNA integrity check. Image taken by
author.
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Immunohistochemical Staining Procedure

Primary antibodies specific for Cluster of Differentiation 68 (CD68) and Cluster of Differentiation
163 (CD163) (Santa Cruz Biotechnology, Dallas, TX) were used to stain macrophages and M2c
macrophages, respectively. CD68 was conjugated with Alexa Fluor 488 and CD163 was conjugated with
Alexa Fluor 647 using APEX Antibody Labeling Kits (Life Technologies, Carlsbad, CA). Tissue sections
were cut at a thickness of ~5µm via a Leica CM3050 S cryostat (Leica Microsystems, Wetzlar, Germany)
o

and mounted on microscope slides. Tissue was then fixed in methanol at -20 C for 20 mins. Tissue
sections were then encircled with a hydrophobic pen and incubated in blocking solution for 30 mins at
room temperature in a humidified chamber. Once blocked, slides were washed 4 times for 5 mins per
wash in phosphate buffered saline (136.9 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4,
pH 7.4). Wash solution was then wicked away from the tissue and tissue was incubated with CD68
o

(1:125 dilution) and CD163 (1:50 dilution) (both diluted in blocking solution) antibodies overnight at 4 C in
a humidified chamber. Slides were then washed 4 times for 5 mins per wash and wash solution was
®

wicked away from the tissue sections using a Kimwipe. VECTASHIELD (Vector Laboratories,
Burlingame, CA) was then applied and cover slips were sealed. Images were then visualized using a
Leica TCS SP5 II confocal microscope (Leica Microsystems, Wetzlar, Germany).

CCL2 Quantification in Microdialysis Dialysates

Dialysates were collected from both the control and treatment probes over a 6 hour period plus
the initial 25 min flush. CCL2 concentrations in the dialysates were determined using a BD OptEIA™ rat
MCP-1 ELISA set (BD Biosciences, San Jose, CA) per the manufacturer's protocol with the exception that
only 60 µL of sample were loaded and the remaining reagents were adjusted accordingly. Briefly, a 96
well plate was blocked for 1 hour, standards of known concentration along with samples were then loaded
and incubated for 2 hours, samples were incubated with enzyme working solution for 1 hour, TMB
substrate solution for 30 mins in the dark, and then the reaction was stopped by adding Stop Solution (1M
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phosphoric acid). The absorbance was then read at 450 nm with a 570 nm reference on a Tecan Infinite
M200 (Tecan, Maennedorf, Switzerland).

Statistical Analysis

A Shapiro-Wilk test was performed to determine normality using Origin 8.6 software. If normality
was not met, a Kruskal-Wallis ANOVA was performed. A Bonferroni post-hoc test was performed to
determine significance, with p≤0.05 being considered statistically significant.

Effects of Delayed Delivery of Dexamethasone-21-Phosphate via Subcutaneous Microdialysis
Implants on Macrophage Activation in Rats

Microdialysis Procedure

CMA 20 microdialysis probes with a 10 mm 100 kDa molecular weight cut-off (MWCO)
polyethersulfone membrane (Harvard Apparatus, Holliston, MA) were used for all microdialysis sampling
procedures. All microdialysis probes were ethylene oxide sterilized (Anderson Sterilizers Inc, Haw River,
NC) prior to use. A BAS Bee microdialysis pump (Bioanalytical Systems Inc, West Lafayette, IN) with 1
mL BAS syringes (Bioanalytical Systems Inc, West Lafayette, IN) were used to perform infusions. All
perfusion fluids were autoclaved and filter sterilized prior to use. Post microdialysis probe implantation,
the inlet and outlet lines were placed in a subcutaneous pocket at the anterior incision. Animals were
then returned to the vivarium until three days post implantation. On days 3-6 post implantation, the
animals were anesthetized, lines removed from the subcutaneous pocket, and placed in a CMA 120
freely moving collection system (CMA Microdialysis, Solna, Sweden).
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Surgical Procedure

All surgeries were performed on male Sprague Dawley rats (Harlan Laboratories, Indianapolis,
IN) in a weight range of 280-315 g. Prior to surgery and post collection, animals were kept in a
º

temperature controlled vivarium at 72 F. Animals were allowed access to food and water ad libitum. All
surgical procedures and experiments were approved by the University of Arkansas Institutional Animal
Care and Use Committee (IACUC) and conformed to the NIH standards for the ethical treatment of
animals.
-1

Animals were initially anesthetized using an induction chamber and 5% isoflurane in 1 Lmin O2.
-1

Animals were then moved to a nose cone where they were maintained using 3% isoflurane in 1 Lmin O2
during the surgical procedure. Body temperatures were maintained using a CMA 150 temperature
controller (CMA Microdialysis, Solna, Sweden) during surgical procedures. All surgical procedures were
performed using aseptic technique. All tools were autoclaved prior to use.
The techniques for implanting microdialysis probes into the rats have been previously described
[6, 7]. Two probes were implanted on opposite sides of the spine with approximately 2.5 cm separation
between them. After collection techniques have commenced each day, the inlet and outlet tubing is
connected with a tubing connector and placed in the subcutaneous pocket. The anterior incision was
then closed using sterile Reflex wound clips (Fine Science Tools, Foster City, CA). On collection days,
animals were anesthetized, the incision was swabbed with alcohol and the lines were removed. All lines
were cleaned with alcohol prior to being placed in the subcutaneous pocket.

Collection Procedure

With two microdialysis probes implanted, one probe serves as a control and the other as the
treatment. The control probe is perfused with Ringer's + 4% Dextran-500 + 0.1% BSA while the
treatment probe is perfused with 20 µg/mL dexamethasone-21-phosphate added. Dexamethasone-21phosphate was used as a derivative which is more water soluble than dexamethasone and is converted
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to dexamethasone by esterases, in vivo [8]. Dextran-500 is an osmotic agent used to reduce fluid loss in
high MWCO probes which has been shown to cause no additional inflammation at the implant site [6].
Bovine serum albumin (BSA) is used in the perfusion fluid to prevent non-specific binding to microdialysis
materials [2]. Prior to implantation, microdialysis probes were flushed with sterile Ringer's. On the third
day post implantation, animals were placed in a CMA 120 freely moving animal system. An initial flush
was performed starting at 3 µL/min and the flow rate was reduced by 0.5 µL/min every 5 mins until a flow
rate of 1 µL/min was reached. Collections were then performed in 1 hr increments for 6 hours. All
collection vials contained Halt Protease Inhibitor, were immediately placed on ice following collection, and
stored at -80ºC following the entire collection period. Following the final collection hour, a final flush was
performed at 3 µL/min for 30 mins. For the final flush, Ringer's or Ringer's + 20 µg/mL Dex were used as
perfusion fluids for the control and treatment, respectively. On the seventh day post implantation, the
animal was euthanized and the probe as well as the tissue surrounding the probe were harvested as
previously described [6]. The probe and tissue surrounding it were then stored in optimal cutting
temperature (OCT) solution and flash frozen using liquid nitrogen for histological and
immunohistochemical analyses or the tissue surrounding the membrane was removed and stored in
RNAlater for qRT-PCR analyses.

qRT-PCR Procedure

Tissue immediately surrounding (~1-2 mm) was harvested from the membrane portion of the
probe and placed in RNAlater and stored on ice. Harvested tissue was stored at 4ºC until RNA was
extracted. RNA was then extracted from the tissue and purified using the Trizol method and an RNeasy
Minikit (Qiagen, Venlo, Limburg). The integrity of the RNA was confirmed by comparing the 18s and 28s
band ratios via gel electrophoresis. RNA was converted to cDNA using a high capacity reverse
transcription kit (Life Technologies, Carlsbad, CA). Gene expression ratios were determined using
Taqman gene expression assays (Life Technologies, Carlsbad, CA) using a 7500 Real Time PCR
instrument (Life Technologies, Carlsbad, CA). Gene expression data were analyzed using REST Gene
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Quantification Software with Taf9b (Transcription initiation factor TFIID subunit 9B) being used as a
control gene.

CCL2 Quantification

CCL2 was quantified in dialysates collected from both the control and treatment probes for each
of the 6 collection hours as well as the initial flush period using a BD OptEIA

TM

rat MCP-1 ELISA set (BD

Biosciences, San Jose, CA). The ELISA was performed per the manufacturer's protocol with the
exception that 50 µL of sample were used and the remaining reagents were adjusted accordingly. Briefly,
a 96 well plate was incubated overnight with detection antibody, the plate was then blocked using assay
diluent for 1 hour, standards and samples were then loaded and incubated for two hours, substrate
solution was then incubated for 30 mins, and the reaction was stopped using stop solution (1M
phosphoric acid). All the appropriate wash steps were performed per the manufacturer's protocol.
Absorbance was then read at 450 nm and a reference of 570 nm was used via a Tecan Infinite M200
(Tecan, Maennedorf, Switzerland).

Immunohistochemistry Procedure

Monoclonal antibodies specific for Cluster of Differentiation (CD) 68 and CD163 (Santa Cruz
Biotechnology, Dallas, TX) were used as a pan macrophage marker and M(Dex) marker, respectively.
Fluorophore conjugation to the antibodies was performed using APEX Antibody Labeling Kits (Life
Technologies, Carlsbad, CA). Alexa Fluor 488 was conjugated to CD68 and Alexa Fluor 647 was
conjugated to CD163. Tissue sections were cut to a thickness of ~5 µm using a Leica CM3050 S cryostat
(Leica Microsystems, Wetzlar, Germany). Sections were then mounted on microscope slides. Sections
were fixed by placing them in cold methanol for 20 mins at -20ºC. The methanol was allowed to dry from
the slide and the tissue sections were encircled with a hydrophobic pen. Blocking solution (PBS + 2% v/v
horse serum + 0.05%(w/v) Tween 20 + 0.0001% (w/v) BSA) was then applied and slides were incubated
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in a humidity chamber for 30 mins at room temperature. Once blocking was completed, slides were
washed 4 times for 10 mins each wash in phosphate buffered saline. Wash solution was then wicked
away from the tissue sections using Kimwipes. Antibodies diluted in blocking solution were then applied
to tissue sections, CD68 (1:125) and CD163 (1:50), and sections were incubated overnight at 4ºC in a
humidity chamber. Slides were then washed 4 times for 10 min per wash and excess wash solution was
wicked away using a Kimwipe. A nuclear counterstain (Hoechst 34580) was then applied to the tissue
sections and allowed to incubate at room temperature for 12 mins in the dark. Slides were then washed 3
®

times for 5 mins/wash and excess solution was wicked away using a Kimwipe. VECTASHIELD (Vector
Laboratories, Burlingame, CA) mounting media was then applied to tissue sections; cover slips were
placed on slides and sealed. All images were obtained using a Leica TCS SP5 II confocal microscope
(Leica Microsystems, Wetzlar, Germany). Images were then subjected to manual counts of cells staining
positive for CD68 as well as CD68 and CD163. Using the data from the manual counts, the percentage
of M(Dex) macrophages was determined.

Histological Analyses

Tissue sections (~5 µm) were obtained using a Leica CM3050 S cryostat (Leica Microsystems,
Wetzlar, Germany) and mounted on microscope slides. Tissue sections were fixed in 10% neutral
buffered formalin. Tissue sections were subjected to hematoxylin and eosin (H&E) as well as Masson's
Trichrome stains. Images were obtained using a Zeiss Axioskop II plus microscope (Carl Zeiss Inc.,
Thornwood, NY) with Cannon EOS Digital Software for Rebel T2i camera.

Statistical Analysis

A Shapiro-Wilk test was performed to determine normal distribution of the data. For CCL2
concentrations, a Kruskal-Wallis ANOVA was performed with a Bonferroni post-hoc test to determine
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significance. For the percent M(Dex) cells present, a two sample t-test was performed to determine
significance. Origin 2015 statistical software was used for all statistical tests.

Effects of IL-10 Delivery at a Non-Degradable Implant Site on Macrophage Activation State via
Microdialysis Sampling in Rats

IL-10 (10 ng/mL) Perfusion

Two microdialysis probes were implanted in the subcutaneous space of male Sprague Dawley
rats. One probe served as a control utilizing Ringer's + 6% Dextran-70 + 0.1% BSA as a perfusion fluid
while the other served as a treatment utilizing the same perfusion fluid with 10 ng/mL IL-10 added. After
probe implantation, animals were moved to a CMA 120 freely moving animal collection system. An initial
flush was performed starting at a flow rate of 3 µL/min and was reduced by 0.5 µL/min every 5 minutes
until a flow rate of 1 µL/min was reached. A one hour perfusion was performed to deliver IL-10 to the
treatment side. After the first hour of perfusion, the treatment perfusion fluid was changed to Ringer's +
6% Dextran-70 + 0.1% BSA, same as the control. Perfusions were performed in 1 hour intervals for the
next 6 hours. Following collections, a final flush was performed with HPLC water (filter sterilized through
0.2 µm PES filter) at a flow rate of 3µL/min for 30 minutes. Dialysates were stored on ice initially, then at
0

-80 C until an ELISA was performed to determine the concentration of CCL2. Animals were then
returned to housing where they remained until 7 days post-implantation. On day 7 post-implantation, the
animals were euthanized and the probe as well as the tissue immediately surrounding the probe was
harvested for histological and immunohistochemical analyses, as previously stated [4] (Fig. 3).
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IL-10 Ultrafiltration

Two microdialysis probes were implanted in the subcutaneous space of male Sprague Dawley
rats. One probe served as a control utilizing Ringer's + 1% Dextran-70 + 0.1% BSA as a perfusion fluid
while the other served as a treatment utilizing the same perfusion fluid with 10 ng/mL IL-10 added. After
probe implantation, animals were moved to a CMA 120 freely moving animal collection system. An initial
flush was performed starting at a flow rate of 3 µL/min and was reduced by 0.5 µL/min every 5 minutes
until a flow rate of 1 µL/min was reached. A one hour perfusion was performed using the 1% Dextran
solution. After the first hour of perfusion, both the treatment and control perfusion fluids were changed to
Ringer's + 6% Dextran-70 + 0.1% BSA. Perfusions were performed in one hour intervals for seven hours.
Following collections, a final flush was performed with HPLC water (filter sterilized through 0.2 µm PES
filter) at a flow rate of 3µL/min for 30 minutes. Animals were then returned to housing where they
remained until 7 days post-implantation. On day 7 post-implantation, the animals were euthanized and
the probe as well as the tissue immediately surrounding the probe (Fig 3) was harvested for histological
0

and immunohistochemical analyses. Dialysates were stored on ice initially, then at -80 C until an ELISA
was performed to determine the concentration of IL-10.
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Fig. 3. Image showing tissue removed from microdialysis probes.
Image taken by author.
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Four Day IL-10 Infusion

Two microdialysis probes were implanted in the subcutaneous space of male Sprague Dawley
rats. One probe served as a control utilizing Ringer's + 6% Dextran-70 + 0.1% BSA as a perfusion fluid
while the other served as a treatment utilizing the same perfusion fluid with 10 ng/mL IL-10 added. After
probe implantation, animals were moved to a CMA 120 freely moving animal collection system. An initial
flush was performed starting at a flow rate of 3 µL/min and was reduced by 0.5 µL/min every 5 minutes
until a flow rate of 0.5 µL/min was reached. A one hour perfusion was performed to deliver IL-10 to the
treatment side. After the first hour of perfusion, the treatment perfusion fluid was changed to Ringer's +
6% Dextran-70 + 0.1% BSA, same as the control. Perfusions were performed in 1 hour intervals for the
next 7 hours at a flow rate of 1 µL/min. Following collections, a final flush was performed with HPLC
water (filter sterilized through 0.2 µm PES filter) at a flow rate of 3µL/min for 30 minutes. Dialysates were
0

stored on ice initially, then at -80 C until an ELISA was performed to determine the concentration of
CCL2. Animals were then returned to housing. The one hour IL-10 infusion was performed every day
until the fourth day post-implantation while the seven hour collections were performed on the day of
implantation and 4 days post-implantation. On day 4 post-implantation, the animals were euthanized and
the probe as well as the tissue immediately surrounding the probe was harvested for histological and
immunohistochemical analyses.

IL-10: 200 and 1200 µg/mL Infusions

Two microdialysis probes were implanted in the subcutaneous space of male Sprague Dawley
rats. One probe served as a control utilizing Ringer's + 6% Dextran-500 + 0.1% BSA as a perfusion fluid
while the other served as a treatment utilizing the same perfusion fluid with either 200 ng/mL or 1200
ng/mL IL-10 added. After probe implantation, animals were moved to a CMA 120 freely moving animal
collection system. An initial flush was performed starting at a flow rate of 3 µL/min and was reduced by
0.5 µL/min every 5 minutes until a flow rate of 1 µL/min was reached. On the day of implantation and four
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days post-implantation, collections were performed for five hours in one hour intervals with the IL-10
being delivered for the entire time in the treatment probe. Following collections, a 30 minute flush at 3
µL/min on the day of implantation was performed but not on day 4 post-implantation. On days 1,2,3 postimplantation, probes were infused for one hour at 1 µL/min followed by a 30 minute flush at 3 µL/min.
The final flush was performed with HPLC water (filter sterilized through 0.2 µm PES filter). Animals were
then returned to housing where they remained until 7 days post-implantation. On day 7 post-implantation,
the animals were euthanized and the probe as well as the tissue immediately surrounding the probe was
harvested for histological and immunohistochemical analyses.
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1. Introduction

Microdialysis sampling is a widely used in vivo collection technique that has been used for more
than 35 years for numerous life science applications [1-3]. This diffusion-based separation method uses
an isotonic perfusion fluid that flows through inlet tubing into an inner cannula, the inner fiber lumen of a
semi-permeable membrane, an outer cannula, and exits via an outlet tube where the dialysate is
collected (Fig. 1). These devices are then implanted into tissue space to allow for collection of solutes
from the extracellular fluid (ECF). The solute concentration gradient that exists between the perfusion
fluid inside the probe and the surrounding extracellular fluid allows analytes smaller than the membrane
molecular weight cutoff (MWCO) to diffuse into the membrane lumen to be collected and then quantified
[4]. The primary reasons for the success and variety of biomedical applications of microdialysis sampling
include 1) it is minimally invasive allowing collections to be performed from targeted tissue sites in awake
and freely-moving animals; 2) analytically-clean samples that require either no or minimal sample
preparation are collected allowing a wide variety of chemical analysis schemes to be applied [5]; 3)
animal numbers can be reduced since the animal in which the probe is placed serves as its own control
significantly reducing the number of animals needed in different studies.
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Fig. 1. Microdialysis probe schematic.
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Microdialysis sampling was originally developed to collect small hydrophilic molecules such as
the catecholamine and amino acid neurotransmitters. With the advent of commercially-available high
MWCO membranes incorporated into microdialysis probes, it is now possible to collect peptides and
proteins of biological significance including cytokines [6-8]. This has opened a wide range of possibilities
for researchers investigating multiple disease states in different tissues that are believed to incur
dysregulated cytokine function [8-15].
Prior to the use of high MWCO membranes during microdialysis sampling, it was common
practice to use a saline solution, such as Ringer's or Ringer’s-Krebs, as a perfusion fluid since these
+

+

solutions contain a balance of different ions (Na , K , Ca

2+

-

and Cl ) believed to exist in the extracellular

fluid space [16]. When Ringer’s solution is the perfusion fluid through a high MWCO membrane, a
significant reduction in expected fluid volumes can be observed due to a difference in hydrostatic
pressure causing the perfusion fluid to pass through the membrane pores. This phenomenon is called
ultrafiltration and would be expected for high MWCO ultrafiltration membranes, which is defined as any
membrane with a MWCO of greater than 50 kDa.
Microdialysis sampling of large bioactive proteins including cytokines can be fraught with two
major difficulties – ultrafiltration and non-specific adsorption to the device materials. Ultrafiltration is
problematic because fluid is lost across the membrane into the tissue resulting in lower than expected
sample volumes. This causes difficulties with chemical analysis techniques such as ELISA that have
defined volume specifications. Additionally, the loss of fluid into the tissue space and its effect on tissue
physiology is poorly understood. Non-specific adsorption is problematic especially with large bioactive
proteins since their concentrations are often in the pg/mL range. If non-specific adsorption is not reduced
by inclusion of albumin as a blocking protein, proteins in such low concentrations may adsorb to the
probe materials precluding their quantitation in dialysates.
When using microdialysis membranes with 100 kDa MWCO or greater, colloids (high molecular
weight dextrans, albumin, or a combination of the two) are added to the perfusion fluid to reduce
ultrafiltration via an increase solution osmotic pressure within the membrane lumen [17, 18]. Bovine
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serum albumin (BSA) and human serum albumin have also been used to reduce ultrafiltration and nonspecific adsorption [19, 20].
An unexplored area of research is whether these added colloids to the microdialysis perfusion
fluid affect the surrounding tissue in deleterious ways. Fluid loss across the membrane may cause
edema or other tissue damage. Albumin (~ 66 kDa), dextran-60, and dextran-70 can diffuse through the
100 kDa MWCO into the tissue. Bovine serum albumin is commonly used in rat studies since it can be
procured at a significantly lower cost than rat serum albumin. However, there are considerable homology
differences between these two albumins that could lead to the potential for immune response.
To date no studies have been performed to determine the effects of commonly used perfusion
fluid reagents, i.e. Ringer's solution, Dextran-70, or BSA, on tissue surrounding implanted microdialysis
probes. Likewise, it has not been determined if there are differences in the tissue reactions to perfused
microdialysis probes vs. non-perfused (simply implanted) probes. These issues related to microdialysis
sampling are critical to elucidate since microdialysis sampling is being widely used to collect cytokines
and other bioactive proteins for various disease states. In this work, we demonstrate that a significant
portion of the trauma caused at the site of a microdialysis probe appears to be due to the act of perfusion
as compared to the implantation process.

2.

Results

2.1 Probe vs. Ringer’s filled probe

Fig. 2 shows the (H&E) and Masson’s Trichrome images for the probes that were either just
implanted (no solution in the membrane fiber lumen) or allowed to have Ringer’s solution reside in the
inner fiber lumen. Cells are seen interrogating both the probe (Fig. 2a) and the Ringer’s fluid-filled probe
(Fig. 2b). No significant difference in the density of cells was observed surrounding either probe. The
Masson’s Trichrome stained sections show more collagen surrounding the probe only (Fig. 2c) as
compared to the Ringer’s fluid-filled probe (Fig. 2d). There appears to be some vascularity surrounding
the probe only (top right of Fig. 2c) whereas no vascularity is seen surrounding the fluid-filled probe (Fig.
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2d). When these images are compared to those for the probes that were continuously perfused with
Ringer’s solution, the similarities in cell density, cellular organization, and collagen formation are striking.
For this reason, all further treatment comparisons are made in relation to probes through which Ringer’s
solution was perfused.
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Fig. 2. Probe vs. Ringer’s Filled Probe.10x Magnification. White size bar represents 100
µm. Top: H&E stain (a) Microdialysis probe implanted in the subcutaneous tissue (no
perfusion fluid). (b) Microdialysis probe with Ringer’s solution residing in the fiber lumen.
Bottom: Masson’s Trichrome stain. (c) Microdialysis probe implanted in the subcutaneous
tissue (no perfusion fluid). (d) Microdialysis probe with Ringer’s solution residing in the
fiber lumen.
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Fig. 3. Ringer’s vs. Ringer’s + Dextran-70.10x Magnification. White size bar represents
100 µm. Top: H&E stain (a) Microdialysis probe with Ringer’s solution perfused. (b)
Microdialysis probe with Ringer’s + 6% (w/v) Dextran-70 solution perfused. Bottom:
Masson’s Trichrome stain. (c) Microdialysis probe with Ringer’s solution perfused. (d)
Microdialysis probe with Ringer’s + 6% (w/v) Dextran-70 solution perfused
.
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2.2 Ringer’s vs. Ringer’s with 6% Dextran-70

With the H&E stain, the probe which had Ringer’s solution perfused through shows cells near the
membrane pores of the probe (Fig. 3a). However, these cells, while well organized, are less densely
packed around the probe as compared to the probe which had Ringer’s with 6% Dextran-70 perfused
(Fig. 3b). The Masson’s Trichrome staining shows far less collagen found around the Ringer’s-perfused
probe (Fig. 3c) as compared to the Ringer’s with 6% Dextran-perfused probe (Fig. 3d), and the collagen
seen around the Ringer’s + Dextran probe consists of thicker strands and is more densely packed than is
seen around the Ringer’s probe. Furthermore, there is a ~25–50 µm thick layer of densely packed cells
immediately surrounding the probe membrane of the Ringer’s with 6% Dextran probe which is lacking in
the Ringer’s-perfused probe site.
Occasionally, probes will fail and fluid flow will no longer be observed exiting the fluid line.
Suspecting that the more pronounced inflammatory response observed for the Dextran-70 infused probes
may be due to Dextran-70 diffusing out of the probe, we decided to let probes that failed remain in the
tissue followed by histological analysis. Fig. 4 shows both the H&E and the Masson’s Trichrome stain for
a microdialysis probe implant that had failed. A significant amount of cellular material is located at the
probe site with the failed probes indicating a nearly necrotic response (Fig. 4a). The space is significantly
inflamed with little collagen remaining as shown in Fig. 4b.
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Fig. 4. Probe Failure with Dextran-70. 10x Magnification. White size bar represents
100 µm.
H&E (Left) and Masson’s Trichrome (Right) stains of an implanted
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2.3 RSA vs. BSA

Fig. 5a and b show the H&E staining for the RSA- vs. BSA-infused probes. Cells are seen near
the pores of the membrane (Fig. 5a and b). While these cells are well organized, they are not as densely
packed as is seen with Dextran. The density of cells surrounding both probes closely resembles that for
tissue surrounding the probes through which only Ringer’s was perfused. Additionally, the amount of
collagen seen around each probe is also similar to that with only Ringer’s perfused (Fig. 5c and d).
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Fig. 5. RSA vs. BSA.10x Magnification. White size bar represents 100 µm. Top: H&E
stain (a) Microdialysis probe perfused with Ringer’s + 3% (w/v) BSA solution. (b)
Microdialysis probe perfused with Ringer’s + 3% (w/v) RSA. Bottom: Masson’s Trichrome
stain. (c) Microdialysis probe perfused with Ringer’s + 3% (w/v) BSA solution. (d)
Microdialysis probe perfused with Ringer’s + 3% (w/v) RSA.
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2.4 Ringer’s + Dextran-500 vs. Ringer’s + Dextran-500 + BSA

The H&E stains for probe explants through which Ringer’s and Dextran-500 vs. Ringer’s,
Dextran-500, and BSA are shown in Fig. 6a and b. Cells appear to be embedded within the membrane
pores in the H&E stained tissue (Fig. 6a and b). There appears to be no difference in the cellular density
around the two probes. The density of cells seen around both probes seems to be the same as is seen in
response to Ringer’s only perfused probes and probes perfused with Ringer’s and either BSA or RSA.
Likewise, cells seen around these probes seem to be less densely packed than what is seen around the
probes which had Dextran-70 infused. Also, there is no layer of extremely densely packed cells
immediately surrounding the probe as is seen in the Dextran-70 infused probes. The collagen content
observed around the two probes is also similar, suggesting there is no difference with respect to the
tissue reaction to this infusion fluid between the two treatments (Fig. 6c and d). The prevalence of
collagen seen around these probes is similar to the collagen seen around the Ringer’s only probe as well
as the Ringer’s with either BSA or RSA.
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Fig. 6. Ringer’s + Dextran-500 vs. Ringer’s + Dextran-500 + BSA. 10x Magnification. White
size bar represents 100 µm. Top: H&E stain (a) Microdialysis probe perfused with
Ringer’s + 6% (w/v) Dextran-500. (b) Microdialysis probe perfused with Ringer’s + 6% (w/v)
Dextran-500 + 0.1% (w/v) BSA solution. Bottom: Masson’s Trichrome stain. (c)
Microdialysis probe perfused with Ringer’s + 6% (w/v) Dextran-500. (d) Microdialysis probe
perfused with Ringer’s + 6% (w/v) Dextran-500 + 0.1% (w/v) BSA solution
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3.

Discussion

The inception of microdialysis sampling was based on an analogy that an implanted microdialysis
sampling probe behaves like a benign capillary in the tissue allowing free diffusion of solutes across its
porous semi-permeable membrane [21]. Despite over 14,000 publications that have used microdialysis
sampling, relatively few have investigated how the implant procedure or the perfusion fluids influence the
tissue surrounding the implant. The majority of the research literature that has described tissue reactions
to microdialysis sampling has been focused on neural tissue [22, 23]. Ultrastructural studies have shown
tissue disruptions to be seen as far as 1.4 mm away from the implant site in the brain [24]. However,
histological analyses of microdialysis probes implanted into other tissues have also revealed the expected
presence of inflammatory cells surrounding the probe implant.
Our group has previously reported, microdialysis probe implants in the subcutaneous space that
only had phosphate buffered saline solution passed through the probes showed a dense, avascular,
cellular layer surrounded by a collagenous, vascular layer at 14 days post implantation [25]. A long-term
investigation of implanted dialysis fibers (not microdialysis probes and not infused) showed that at 3
weeks the probes were encapsulated by a highly cellular disorganized capsule, at 6 weeks a highly
cellular yet highly organized capsule, and at 12 weeks a mature fibrotic capsule was seen characterized
by low cellularity and dense bands of collagen on the membrane surface [26]. These results are
consistent with Sanders' study which showed that a height threshold of 5.9 µm exists and is the most
important factor in determining the formation of a fibrotic capsule around an implant [27]. The
microdialysis probes used in this study had an outer diameter of 500 µm which exceeds the 5.9 µm
reported as the threshold indicating that a fibrotic capsule would be expected. However, while the effects
of implanting different types of polymeric membranes have been investigated, no investigations have
looked at the effects of perfusion fluid components i.e. Dextran, BSA, and RSA with respect to their effect
on tissue responses to the microdialysis probe implant.
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Our work is the first to demonstrate that perfusion fluid additives used for microdialysis sampling
lead to different inflammatory responses. While the insertion of a microdialysis probe is considered to be
minimally invasive, it must be recognized that there is a certain amount of trauma associated with the
implantation procedure. This can be seen by the densely packed cells surrounding an implanted
microdialysis probe. These cells are responsible for the initial clearance of any cellular debris, the
formation of the fibrotic capsule, and the eventual wound healing process. While the trauma due to probe
implantation cannot be avoided, it is important to minimize the trauma due to the sampling procedure to
gain a better understanding of the biochemical processes occurring at the implant site. While we have
shown that there are differences in the cellular response seen surrounding a Ringer's perfused probe as
compared to an implanted microdialysis probe where no perfusion occurs, they can be considered
negligible. Given the nature of microdialysis sampling experiments in that the technique is used to
sample from tissue, it is unavoidable to prevent a perfusion and thus the low-level inflammatory response
to the perfusion fluid will be present.
The inclusion of high MWCO membranes into microdialysis probes has allowed for the collection
of larger molecular weight solutes such as bioactive proteins. The tradeoff is that ultrafiltration, or loss of
fluid across the membrane pores, can become a significant problem. To circumvent this problem,
osmotic agents such as Dextran-60 (~ 60 kDa) or -70 (~70 kDa) were being added at high concentrations
(1 to 4% w/v). These agents have since been widely used in microdialysis sampling with 100 kDa MWCO
membranes [11, 15, 28-42]. Our results show that Dextran-70, when allowed to enter the extracellular
space, causes an intense inflammatory response. While theoretically the use of Dextran-70 in perfusion
fluids could result in the dextran leaving the probe, it has never been determined if its use results in an
increased inflammatory response at the implant site. We found that Dextran-70 diffuses out of the probe
resulting in increased inflammation at the probe site. This response cannot be seen as negligible and
must be considered when collecting bioactive proteins such as the cytokines.
Due to the fact that Dextran-70 was shown to invoke an inflammatory response when perfused
through the probe, alternative osmotic agents were tested. The use of BSA is commonly used in
perfusion fluids at high concentrations (3.5-10% w/v) to reduce fluid loss [19]. Simultaneously, low
concentrations of BSA (~0.1% w/v) have been used in perfusion fluids to prevent non-specific binding of
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proteins to the microdialysis outlet tubing. Theoretically, BSA (~66,000 Da) could exit the probe yet its
effects on the tissue surrounding the implanted microdialysis probe have never been studied. Our results
show that the tissue surrounding a BSA treated probe shows no appreciable difference to tissue seen
surrounding a RSA treated probe or a Ringer's only perfused probe. This suggests that there is no
significant inflammatory reaction seen in response to the BSA.
While the use of BSA as an osmotic reagent was shown to have no inflammatory effect on the
tissue, it was shown to give lower fluid recoveries (data not shown) as compared to Dextran-70. Dextran500 has been shown to give fluid recoveries of 100% when used at lower flow rates [43]. In fact, we have
found that Dextran-500, when used at 6% w/v, yields 100% fluid recovery in vitro (data not shown).
Dextran-500, with or without 0.1% BSA, has also been shown to result in no additional inflammatory
response as compared to Ringer's only perfused probes in vivo. While the data presented here shows
Dextran-70 causes an inflammatory response in vivo, Dextran-500 appears to be a viable alternative as it
retained the fluid recovery without causing an excessive inflammatory response.

Conclusion

While microdialysis sampling has gained popularity, there have been no studies reporting the
effects of perfusion fluid components on inflammation surrounding the probe. In this study we
investigated the effects of the actual perfusion of fluid through the probe, Ringer's solution, Dextran-70,
BSA, RSA, and Dextran-500 on the tissue surrounding the probe. What we found shows that the use of
Dextran-70 in the perfusion fluid results in some of the Dextran diffusing into the ECM. The result of this
Dextran diffusing out is highly inflamed tissue seen surrounding the probe. For this reason, we would
suggest that Dextran-70, or any lower molecular weight Dextran, not be used in perfusion fluids during
microdialysis sampling. Instead, we would suggest the use of Dextran-500 as this does not diffuse out of
the probe and appears to not cause additional inflammation on top of the inflammation that is caused by
the surgical implantation process.
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1. Introduction

Macrophages play key roles in both innate and adaptive immunity. Their importance to the field of
biomaterials has been recognized for decades [1, 2]. Macrophages are known to play opposing roles
such as inflammatory vs anti-inflammatory and tissue destruction vs tissue remodeling. The macrophage
role is driven by micro-environmental chemical signals present within the extracellular matrix. These cues
result in different macrophage polarization states [2-4], which comprise a continuum of macrophage
phenotypes. In the case of bacterial infections, pro-inflammatory cytokines, such as Interferon-gamma
(IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α), are released, inducing an M1-type macrophage. This
macrophage phenotype is responsible for a Th1 type response resulting in a pro-inflammatory,
phagocytic response that effectively clears pathogens. M1 macrophages are further characterized as
producing high levels of pro-inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-12 and TNF-α [57].
At the other end of the polarization continuum are the M2 macrophages, which are subdivided
into three classifications: M2a,b,c [6]. The M2a macrophages are induced by IL-4 and/or IL-13. This
polarization state is thought to promote a Th2 type response and the formation of foreign body giant cells
(FBGC), as well as clearance of parasites [6].

M2a macrophages are characterized as producing

collagen type VI, fibronectin, Transforming Growth Factor Beta (TGF-β) and Transforming Growth Factor
Beta Induced (TGFβI) [8]. M2b macrophages are induced by FC gamma receptors and toll-like receptor
activation.

M2b macrophages are characterized as producing high levels of the anti-inflammatory

cytokine, IL-10, but also high levels of inflammatory cytokines such as IL-1β, IL-6 and TNF-α [2]. M2c
macrophages are induced by IL-10 and glucocorticoid steroids and are characterized as producing high
levels of IL-10 and low levels of inflammatory cytokines such as IL-1β, IL-6 and IL-12 [5].

M2c

macrophages are thought to be anti-inflammatory, pro-wound healing, and pro-tissue remodeling cells.
A recent publication by Murray et al. provides suggestions for a nomenclature change for
macrophage polarization states [9].

These authors suggest that instead of using the M1, M2

nomenclature that the polarizing agent be used to identify the macrophage such as M(LPS) for LPS
induced macrophages as a replacement for M1 or M(GC) for macrophages induced by glucocorticoids
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instead of M2c [9].

In accord with these newly suggested guidelines, this paper will use the new

nomenclature for descriptions of specific subtypes of macrophages elicited in this study.
Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, is a
13kDa monomeric chemokine [10]. Chemokines are responsible for the recruitment of leukocytes such
as monocytes, neutrophils, and lymphocytes, to a wound via chemokine gradients. CCL2 is known to be
one of the primary chemokines responsible for the migration and infiltration of monocytes to a wound site
[11]. CCL2 has been implicated in biomaterials contexts for attracting monocytes to the site of an implant
[12]. Once at the wound site, monocytes differentiate to macrophages. Depending on the cytokine
signals present at the wound site, these macrophages will then polarize to either a predominantly M1 or
M2 state.
Glucocorticoid steroids are a class of steroids that bind to the glucocorticoid receptor which
regulates inflammation and have been used extensively to treat inflammatory conditions [13, 14].
Dexamethasone, a synthetic glucocorticoid steroid, has been shown to regulate pro-inflammatory
cytokines in two ways: (1) the glucocorticoid receptor interacts directly with glucocorticoid response
elements in the promoter region of genes, thereby inhibiting gene expression [15, 16], (2) by interfering
with transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) and
Activator Protein 1 (AP-1) [17-19].

Glucocorticoids have been shown to reduce the transcription of

several genes including CCL2, IL-6, and TNF-α and inducible Nitric Oxide Synthase (iNOS) [20] as well
as reducing protein levels of CCL2 in plasma and granuloma tissue [13, 21, 22], IL-6 in plasma and
sponge exudate [23, 24], and TNF-α in sponge exudate [24]. In human monocytes, dexamethasone has
been shown to induce a specific anti-inflammatory subtype marked by the up-regulation of many antiinflammatory genes and the down regulation of pro-inflammatory genes [25].
Dexamethasone has been widely used in the field of biomaterials to reduce inflammatory
responses to implanted materials [26, 27]. There are numerous examples of the use of dexamethasone
to reduce inflammation in a biomaterials context [14, 28-31]. However, the endpoint analyses in these
studies are frequently histological analysis of H&E and Masson’s Trichrome stains.
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Microdialysis sampling is a widely-used, minimally-invasive, diffusion-based in vivo collection
technique in which a probe, with a defined molecular weight cut-off (MWCO) semi-permeable membrane,
is surgically implanted allowing in situ collection of many different solutes [32]. An isotonic fluid with a pH
and ionic strength matching the extracellular space (ECS) is perfused through the membrane lumen in
contact with the extracellular fluid allowing free solute exchange and collection of solutes. Since a solute
concentration gradient exits between the perfusion fluid and the ECS, solutes diffuse into the membrane
lumen and the resulting dialysate is collected and quantified [33]. This allows microdialysis to be used to
simultaneously collect analytes from the ECS as well as deliver modulators to the ECS provided they are
smaller than the MWCO of the membrane [34].

Dexamethasone-21-phosphate is a water-soluble

derivative of the hydrophobic dexamethasone that is converted to dexamethasone in vivo by esterases
[35].
Macrophage polarization in the context of biomaterials has been identified as an important
process to consider when developing materials that can integrate with the host and provide improved
outcomes [36]. Much effort has been focused on reducing the FBR to implanted sensors. Thus, having
means to control this outcome via macrophage polarization that provides acceptable outcomes would be
highly beneficial to many biomaterials applications. While there has been significant work on macrophage
polarization in vitro, there are relatively few in vivo reports. Knowing that M2c macrophages are prowound healing and pro-tissue remodeling, it has been postulated that if modulators can be used to shift
macrophages to a predominately M2c state, the longevity of the implant would be expected to increase.
In this work, microdialysis sampling probes have been used to locally deliver dexamethasone-21phosphate at an implant site to alter the cytokine environment toward polarizing macrophages to their M
(GC) state.

To assess if cytokine responses were altered from the dexamethasone treatment, we

quantified CCL2 protein levels in dialysates and performed gene expression studies combined with
immunohistochemistry of the tissue surrounding the microdialysis probe implant.
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2. Results

2.1 qRT-PCR

Transcription levels of seven different genes (Arginase (Arg2), CCL2, CD163, IL-6, iNOS2, TGFβ, and TNF-α) were analyzed using qRT-PCR from the extracted tissue in which the microdialysis probe
was implanted (Figure 1). CCL2, IL-6, TGF-β, and TNF-α were chosen as markers to determine if Dex
had any effect on the cytokine environment which would be expected in the FBR. Both IL-6 and CCL2
transcript levels were found to be significantly reduced, 2.7 fold (p≤0.01) and 3.4 fold (p≤0.001)
respectively, in response to the Dex treatment as compared to controls. The transcription levels between
TNF-α and TGF-β showed no significant difference between Dex treatments and controls. CD163, Arg2,
and iNOS2 were chosen to investigate the effects of Dex on known differential markers for macrophage
polarization state at the implant site. Transcript levels of CD163, Arg2, or iNOS2 were unchanged in
response to Dex treatment as compared to controls.
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Fig. 1. Relative gene expression ratios from excised tissue in response to Dex (20
µg/ml) infused as compared to controls (n = 3). Error bars represent the SEM with
*p ≤ 0.01, *p ≤ 0.001.
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2.2 CCL2 quantification

Figure 2 shows the CCL2 concentrations in dialysates from control and treatment probes. On the
day of implantation (Fig 2a) CCL2 concentrations from the control probes steadily rose over the 6 hour
th

collection period ranging from ~100 pg/mL in the first hour of collection to ~1300 pg/mL by the 6 hour. In
dialysates collected from the Dex-treatment probes, CCL2 concentrations were found to be ~100 pg/mL
st

during the 1 hour, and peaked during hours 2 through 4 to a level of approximately 400 pg/mL. During
hours 5 and 6, CCL2 concentrations decreased to ~200 pg/mL. There was no significant difference in
CCL2 levels found in control and treatment dialysates in the flush or hours 1 through 4. In hours 5 and 6,
CCL2 levels in the treatment were found to be significantly lower (~200 pg/mL) than in control (~ 1200
pg/mL).
One day post implantation (Fig 2b), CCL2 concentrations collected from control probes ranged
from 1100 pg/mL to 600 pg/mL during the collection period (1 to 6 hrs), decreasing from 1-3 and
stabilizing over hours 4-6 but showing no statistical difference over the collection period.

CCL2

concentrations collected from treatment probes decreased from ~750 to ~300 pg/mL during hours 1
through 3, remained constant in hour 4 and decreased in both hours 5 and 6 to a level similar to the first
hour of collection on the day of implantation.

No significant difference was seen between CCL2

concentrations collected from control and treatment probes during the flush or hours 1, 2, and 4, but
CCL2 concentrations were found to be significantly lower in the treatment probes as compared to the
control probesin hours 3,5, and 6.
Two days post implantation (Fig 2c), CCL2 concentrations from control probes ranged from ~750
pg/mL to ~400 pg/mL and seemed to remain stable over the collection period showing no statistically
st

significant difference. CCL2 concentrations from treatment probes were ~450 pg/mL during the 1 hour
of collection and steadily decreased during the 6 hour collection period. During hours 3 through 6, CCL2
concentrations in dialysates collected from treatment probes were significantly lower than CCL2
th

concentrations in dialysates collected from control probes. Furthermore, by the 6 hour of collection, two
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days post implantation, Dex reduced CCL2 concentrations from the treatment probes to the level that was
seen during the initial flush on the day of implantation.
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Fig. 2. Bar graphs showing the concentration of CCL2 collected from the control and treatment
-1
probes perfused at 1 µl min for each hour on the day of implantation (top, 2a), 1 day post
implantation (middle, 2b), and 2 days post implantation (bottom, 2c). Error bars represent the
standard error of the mean with *p ≤ 0.05 for n = 8 (top) and n = 6 (middle, bottom) animals. F
represents the initial flush period.
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2.3 Immunohistochemistry

Immunohistochemistry was used to identify macrophages in the tissue surrounding an explanted
microdialysis probe using a CD68 antibody. To determine if Dex caused macrophages to convert to the
M(GC) polarization state and formerly called M2c state, a CD163 antibody was used to
immunohistochemically stain these types of macrophages. At lower magnifications (20x) there appeared
+

to be no CD163 cells immediately surrounding the microdialysis probe (Figure 3A).

At the lower

+

magnification, pockets of CD163 cells were seen more distal (350-500 µm) to the microdialysis probe in
both control and treatment tissue, with these cells appearing to be more distal to the control probe (Figure
+

3A). However, at higher magnification (40x) it was found that CD163 cells are present in both control
and treatment tissue immediately surrounding the microdialysis probe (Figure 3B). Further, in the higher
+

magnification images, it can be seen that there is a greater amount of CD163 cells surrounding the
+

treatment probe than the control (Figure 3B). The percentage CD163 cells found in the 40x images were
+

calculated for both treatment and control. The percentage of CD163 cells found was significantly greater
in the treatment tissue than in the control tissue (Figure 4).
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Fig. 3. Immunohistochemical staining for CD68 (green), CD163 (red) and nuclei (blue) in tissue
surrounding a microdialysis probe. Overlapping colors represent M(GC) macrophages. (A) Images
of both control and treatment tissue surrounding a microdialysis probe membrane, 20x
magnification. (B) Images of both control and treatment tissue surrounding a microdialysis probe
membrane, 40x magnification. (C) Images of isotype controls, 20x magnification. (D) Images of
isotype controls at 40x magnification. M indicates the microdialysis probe membrane. Scale bars in
lower right of each image represent 100 µm
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Effect of Dex-21-P on the Percentage of M2c Macrophages
Surrounding a Microdialysis Membrane
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Fig. 4. Graphical representation of the percentage of CD163 (M(GC)) cells
found in both control and treatment tissue. Error bars represent the standard
error of the mean. n = 5 where n is equal to the number of measurements *p
≤ 0.05.
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2.4 Histological analyses

Histology (H&E and Masson’s Trichrome) was performed to determine the effects of Dex on the
cellular density and collagen amounts surrounding the probe (Figure 5). The Dex-treated tissue was
more fragile than control tissue resulting in unusable treatment sections. The Dex-treated tissue fragility
may be a result of reduced cellular density. Tissues with Dex treatment are often difficult to process since
the tissue surrounding the implant is not well integrated. In the cases where sections were obtained, it is
clear the Dex treatment has reduced the number of infiltrating cells.
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Fig. 5. H&E and Masson’s Trichrome staining of the tissue surrounding the microdialysis probe
implanted into the subcutaneous space. Top: (H&E) stained tissue (nuclei: blue; eosinophilic structures:
red; basophilic structures; purple; erythrocytes: bright red). (A) Control microdialysis probe. (B)
-1
Treatment microdialysis probe (20 µg ml Dex). Bottom: Masson’s Trichrome stained tissue (nuclei:
dark brown/black: cytoplasm: light red/pink: collagen: blue). (C) Control microdialysis probe. (D)
-1
Treatment microdialysis probe (20 µg ml Dex). Images are 10x magnification with 100 µm scale bar
and are representative of tissue where tissue sections were obtainable.
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3. Discussion

The implantation of biomaterials is known to lead to the FBR and eventual fibrotic encapsulation.
While the encapsulation of some biomaterials is not problematic, other biomaterials suffer from loss of
reliable function due to encapsulation [37]. In the case of degradable biomaterials, the formation of scar
tissue at the implant site as opposed to wound resolution is considered problematic. Until recently, these
tissue outcomes of biomaterial implantation were viewed as detrimental, yet unavoidable.
Macrophage polarization has been described as playing a potential key role in the outcome of
biomaterial implantation [36]. Controlling macrophage polarization states at an implant site may lead to
improved tissue remodeling and reduced fibrosis and has been the topic of several recent review articles
[38-40]. However, the available literature describing macrophage polarization as an observed outcome in
biomaterials studies are limited. Most of the macrophage polarization literature is derived from the field of
tumor biology. One recent work has used genetic engineering of IL-10 to different types of macrophages
in cell culture to promote macrophage polarization [41]. The same group has used genetic engineering
techniques in tissue to alter leukocyte infiltration in vivo [42].
Use of microdialysis sampling procedures allows both the localized delivery of modulators to the
tissue space and a concomitant collection of bioactive solutes that may be affected by the modulator.
This characteristic makes microdialysis sampling a useful model technique in biomaterials science for
investigating responses to locally-delivered modulators and their effects on the local tissue biochemistry.
Solutes collected by the microdialysis probe reflect the localized chemical milieu surrounding the
implanted microdialysis probe. Combining bioactive chemical content analysis with tissue analysis that
includes judicious choices regarding gene transcription coupled with immunohistochemical staining of
defined macrophage surface markers provides a comprehensive approach for elucidating the molecular
mechanisms of macrophage polarization in vivo.
Dexamethasone was used in this study for several reasons. First, glucocorticoids are known to
dampen inflammation and Dex has been shown previously to reduce fibrosis at an implant site and has
been widely applied in biomaterials studies [26, 43]. Additionally, Dex is known to induce macrophages
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to an M(GC) state which was our desired goal in these experimental studies. Dex likely reduces fibrosis
at implants due in part to Dex's ability to decrease pro-inflammatory cytokines at both the gene and
protein level [44, 45]. It is interesting to note that most of the work with biomaterials and Dex for in vivo
studies have relied on histological outcomes and have not elucidated alterations in molecular
mechanisms in vivo. To our knowledge, this work is the first that aims to gain a more complete molecular
snapshot of how modulators affect the FBR in vivo.
Dexamethasone delivery from the microdialysis probe caused significant decreases in both IL-6
and CCL2 at the gene transcript level. Since both of these cytokines are considered to be inflammatory, it
is expected that Dex treatment would cause significant decreases in their overall transcript levels. While
PCR analysis has been used to elucidate gene transcript changes in the presence of implanted
biomaterials in an in vivo setting [46], it has not been used in vivo in the context of using modulators to
affect macrophage polarization. The changes in transcription levels with Dex are in accordance with
previous studies which have shown Dex treatment to be able to reduce transcript levels of CCL2 in rat
pancreatitis models [17] as well as in an inflammatory state induced by potassium permanganate [21].
Dex has been shown to reduce IL-6 transcript levels in a rat arthritis model [47].
While Dex significantly decreased CCL2 and IL-6 gene transcripts, it did not significantly change
the gene transcripts for another inflammatory cytokine, tumor necrosis factor-α (TNF-α). While this was
unexpected, it is not novel in that TNF-α levels have been shown to be constitutively expressed in the
spleen, liver, and small bowel of rats even when treated with Dex [48]. Further, TNF-α transcript levels
have been shown to rise immediately following Dex treatment in a rat arthritis model [47]. The remaining
genes showed no differential expression due to Dex treatment.
In the case of TGF-β1, reports of transcript regulation have been controversial. Dex has been
shown to have different effects including no changes in TGF-β1 transcript levels in human T cells
collected from asthma patients [49], increases in TGF-β1 transcript levels in human T cell cultures [50] as
well as decreases in TGF-β1 transcript levels in rats [51].

The effect Dex has on TGF-β1 may be

transient and dose dependent and perhaps the time course and/or dosage was unable to produce a
difference in TGF-β1 transcript levels.
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The genes for CD163, Arg2, and iNOS2 were chosen for analysis based on reports of differential
expression of their protein products in an M(GC) state. While transcript levels of CD163, Arg2, and
iNOS2 were unchanged, this does not mean that protein levels also remained unchanged as changes in
transcript and protein levels do not always share a correlated response [52, 53]. Since quantitative
analysis was not performed on Arg2 or iNOS2 protein concentrations, it is not possible to determine if
these protein levels changed in response to the Dex-treatment.

However, evidence of increased

expression of CD163 was found using immunohistochemical staining. This increase may be due to tissue
being harvested and RNA processed after the transcript levels peaked. Alternatively, this may be due to
the relative amount of total tissue obtained relative to that which would be nearest to the microdialysis
probe releasing Dex.
CCL2 is a chemokine known to recruit monocytes to a site of inflammation. Dex reduces CCL2
concentrations in rats during different inflammatory states in both plasma and whole tissue [13, 17, 21].
On the day of implantation, a steady increase in CCL2 concentration was quantified in the dialysate of the
control probe during the collection period. This was expected as CCL2 is needed at the wound site to
recruit macrophages. On one and two days post implantation, no statistically significant difference was
seen in CCL2 concentrations over the 6 hour collection period, possibly in result of CCL2 reaching
homeostasis. Interestingly, in the dialysate from the treatment probe, an increase in CCL2 concentration
is seen between the first and second hour followed by a decrease in the fifth and sixth hours of collection
on the day of probe implantation. This suggests that while the Dex may begin exerting anti-inflammatory
effects as early as two hours post administration, as indicated by the leveling off of CCL2 concentrations
in the treatment dialysates, the anti-inflammatory effects do not peak until later time points as indicated by
suppression of CCL2 amounts quantified.

On the following two collection days a general trend of

suppression of CCL2 in treatment dialysates was seen in response to Dex, with the CCL2 concentration
by hour 6 two days post implantation being similar to the concentrations initially detected after
microdialysis probe implantation. Interestingly, CCL2 concentrations were found to be much higher in the
initial hours of collection as compared to the final hours of collection the previous day. In fact, CCL2
concentrations in the initial flush each day showed no difference between control and treatment
dialysates even though Dex was allowed to remain in the probe overnight and freely diffuse out into the
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ECS from the treatment probe. It is not entirely clear why this has been observed. The lack of difference
in the initial flush may suggest that a certain continuous dose has to be applied. Alternatively, from an
area-under-the-curve approach, it is clear the overall amount of CCL2 is significantly lower surrounding
the probe.

This could be a combination of diffusion/mass transport changes combined with CCL2

generation that lead to these differences.

If CCL2 is being produced or generated locally by

macrophages in the control implant, then its concentration will not be drained from the tissue space
through the continuous sampling (removal) process with the microdialysis sampling probe.
Glucocorticoids, such as Dex, have been reported to shift macrophages to a predominantly M2c
(M(GC)) state [5, 6].

In a recent study it was shown that dexamethasone was able to shift human

macrophages to an M2c (M(GC)) state resulting in increased CD163 expression and increased clearance
of early apoptotic cells, in vitro [54]. The desire to shift macrophages to an M2c (M(GC)) state at an
implant site is based on the hypothesis that by doing so the implant will better integrate into the
surrounding tissue resulting in reduced fibrosis, reduced failure rates, and improved healing. Badylak's
group has shown that a predominantly M2c macrophage response to a scaffold implantation results in
improved healing and integration of the scaffold [55, 56]. It is important to note at this point that while the
Badylak group's findings are important, they differ from this work in that (1) they investigated degradable
biomaterials whereas our study utilizes a non-degradable biomaterial, (2) the Badylak group looked at the
polarization state of macrophages as a predictor of outcome in response to different biomaterials whereas
we focus on using a modulator to shift the polarization state of macrophages at an implant site. However,
the same factors can be used as a predictor of outcome.

What we found was that two distinct

populations of macrophages were found surrounding the implant at lower magnification (20x). This gave
+

-

the appearance that tissue proximal to the implant was predominantly CD68 CD163 macrophages, while
+

+

tissue more distal from the probe was predominantly CD68 CD163 macrophages, representing the
expected conversion for M(GC) macrophages.

This finding is in concert with a previous report that

showed areas of predominantly M2 macrophages at the periphery of an implant, though these cells were
stained with the pan M2 marker (CD206) and not CD163, which is an M2c specific marker [57]. However,
+

upon further investigation, we found that at higher magnification CD163 macrophages were seen in
+

areas proximal to the probe. Further, we found that there were more CD163 macrophages surrounding
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the treatment probe as compared to the control probe. We also found that the tissue surrounding the Dex
+

probes contained a significantly higher percentage of CD163 macrophages. This suggests that Dex is
able to shift macrophages to a pro-wound-healing state in vivo.
Previous studies have used different biomaterials to release Dex in an effort to reduce fibrosis
using histological analyses as an endpoint [14, 28, 29, 31, 58]. Our own histological findings are similar
to this previous work since Dex is able to reduce the cellular density surrounding the biomaterial.
However, it should be noted that these studies have a wide range (5.3 µg-7 mg) of Dex being delivered to
the biomaterial implant site. These are much higher doses than used in this study, with the amount of
delivered Dex being ~3.6 µg per 6h collection period, giving a total of ~10.8 µg of Dex being delivered
over the three days. It is important to note that these numbers do not take into account the Dex which
was left in the probes at the conclusion of each sampling period and allowed to freely diffuse out.
Interestingly, even though less Dex was delivered in this study, our findings are consistent with previous
findings which showed Dex to result in a decrease in the amount of infiltrating cells [14, 28, 29, 31, 58].
This may be due in part to the fact that our technique does not suffer from the initial high bursts of drug
that is commonly associated with controlled release biomaterials.

106

4. Conclusions

Implanted microdialysis sampling probes were used to locally deliver Dex to the subcutaneous
space of rats. This treatment altered the localized concentration of the chemokine, CCL2, and damped
gene transcription for CCL2 and IL-6. While no changes in gene transcription were observed for the
macrophage CD163 protein, this marker was identified in immunohistochemical analyses. While different
materials have been used successfully in vivo to polarize macrophages to a pro-wound healing M2c
+

(CD163 ) state, the use of modulators to shift macrophage polarization states has been focused primarily
on in vitro studies. The ability to bridge the gap between successful in vitro modulators and in vivo
implants could result in improved tissue remodeling outcomes to a host of biomaterials. This study is the
+

first to show that Dex can be used to shift macrophages to a CD163 state at a non-degradable implant
site. While this study has some limitations with respect to a limited number of markers and investigation
as to the long-term effects on tissue remodeling, it shows great promise for the ability to use modulators
to shift macrophage polarization states in vivo resulting in improved tissue remodeling.
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1. Introduction

Millions of different types of biomaterials (artificial heart valves, breast implants, implanted
biosensors, pacemakers, and prosthetic joints) are implanted worldwide every year. Each of these
different biomaterials elicits a foreign body reaction (FBR) which is an immune response to the implanted
biomaterial [1]. While normal wound healing consists of hemostasis, inflammation, proliferation and
remodeling, the FBR consists of acute inflammation, chronic inflammation, and the eventual fibrotic
encapsulation of the biomaterial. This encapsulation results in the biomaterial being 'walled off' from the
rest of the body, residing in its own microenvironment. For many biomaterials, this encapsulation poses
no significant clinical concerns, but for other materials such as sensors, this encapsulation proves to be
detrimental resulting in loss of function [2]. For this reason, much effort has been put into controlling or
altering the FBR to eliminate or reduce the formation of the fibrotic encapsulation.
Macrophages play a role in both innate and adaptive immunity and can phagocytose foreign
materials including microbes and cellular debris [3]. Beyond being phagocytic cells, macrophages play
dueling roles in both driving and resolving inflammation, antigen presentation vs. scavenging, and tissue
destruction vs tissue remodeling. Macrophages have been historically-identified as playing a critical role
in the outcome of implanted biomaterials and their FBR [4].
Macrophages are highly plastic cells exhibiting a wide range of phenotypes [5]. Macrophage
activation is a term used to describe the ability of macrophages to change phenotypes in response to
biochemical signals [6, 7]. Mills identified this phenotypic change as macrophage polarization and
identified the extremes of these phenotypes along this plastic continuum as either M1 or M2 [8]. M1
macrophages are classically activated by lipopolysaccharide (LPS), interferon gamma (IFN-γ), or tumor
necrosis factor alpha (TNF-α). M1 macrophages secrete pro-inflammatory cytokines (IL-1β, IL-6, IL-12,
and TNF-α) and high concentrations of nitric oxide [7, 9]. M1 macrophages are characterized as being
pro-inflammatory, highly microbicidal, and efficient antigen presenting cells expressing high amounts of
major histocompatibility complex II (MHC II) [10]. M2 macrophages consist of three subclasses, M2a,b,c,
and are considered to be anti-inflammatory. M2 macrophages are induced by a variety of different
modulators, IL-4 and/or IL-13 (M2a), immune complex, toll-like receptor, or IL-1 receptor ligation (M2b)
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and IL-10, glucocorticoids, and secosteroids (M2c) [10, 11]. M2c macrophages are considered to be antiinflammatory, pro-tissue remodeling, and pro-wound healing. Macrophage activation has become of wide
interest in the fields of biomaterials and regenerative medicine [12-15]. It has been postulated that by
switching macrophages to a predominantly M2c activation state at an implant site, improved wound
healing and improved implant integration into the host tissue will be achieved. Recently, a nomenclature
change was requested to denote macrophage polarization as macrophage activation with the
macrophage phenotype being termed according to the modulator which was used to elicit the
macrophage, i.e., M(LPS) rather than M1 [16]. In this paper, the M1/M2 nomenclature will be used as a
broad categorization for comparisons to past literature while the modulator nomenclature, M(Dex), will be
used to describe macrophages that were altered via the delivery of Dex through the implanted
microdialysis probe.
Microdialysis sampling is a minimally-invasive, diffusion-based sampling technique [17]. The
microdialysis probe consists of an inlet and outlet tubing, inner cannula, and a semi-permeable
membrane with a defined molecular weight cut-off (MWCO). Microdialysis sampling has been used in
vivo to sample low molecular weight soluble analytes from the extracellular space (ECS) which are
smaller than the MWCO of the probe membrane. This technique works by passing a fluid (perfusate),
which is of physiological ionic strength and pH, through the inlet and down the inner cannula. Once the
perfusate leaves the inner cannula, it passes by the membrane and exits through the outlet tubing and is
collected as a dialysate. Any concentration gradient which exists between the perfusate and the ECS
allows the diffusion of molecules into or out of the microdialysis probe. This feature allows microdialysis
sampling to be used for the simultaneous collection of analytes from and delivery of modulators to the
ECS [18]. Once collected, analytes in the dialysate can be quantified using a wide variety of chemical
analysis methods.
Dexamethasone (Dex) is a synthetic glucocorticoid that is widely used as an anti-inflammatory
and immunosuppressant drug [19, 20]. Once inside the cell, dexamethasone binds to glucocorticoid
receptors which then translocate to the nucleus [21]. In the nucleus, Dex carries out its anti-inflammatory
effects via two means: transactivation and transrepression [22]. Transactivation is the increase in the
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expression of certain anti-inflammatory genes including lipocortin-1 and the type II IL-1 receptor [23, 24].
Transrepression is the down regulation of pro-inflammatory genes through the direct binding of the
glucocorticoid receptor to negative glucocorticoid receptor elements [25, 26] and by interfering with
activator protein-1 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [27, 28].
Through these actions Dex has been shown to down-regulate pro-inflammatory cytokines such as CCL2,
IL-6, and TNF-α at the transcriptional level [29] as well as reducing CCL2, IL-6, and TNF-α protein
concentrations in different animal models [30].
Chemokine (C-C motif) ligand 2 (CCL2) is a 13 kDa chemokine which exists as a monomer and
homodimer at physiological concentrations [31]. CCL2 was formerly known as monocyte chemoattractant
protein-1 (MCP-1) due to its ability to result in monocyte migration. CCL2 has been shown to be one of
the primary factors for attracting monocytes to a wound site [32]. Once at the wound site the monocytes
differentiate into macrophages. The activation state of these macrophages depends on the biochemical
milieu present at the wound site.
Dexamethasone has been widely used as a release agent from biomaterials studies in an effort to
improve integration of the biomaterial with the host tissue [33]. Dex has also been identified as a
modulator which produces a phenotype that has characteristics of the former M2c macrophage [7, 10].
While much work has been done with incorporating Dex-release into implanted biomaterials, quantifying
the molecular response, particularly in vivo attempts to shift macrophages to an M(Dex) phenotype has
not been reported. Most work with Dex-releasing biomaterials uses standard histological, rather than
molecular assessments, of implant/tissue outcomes. Our previous work has shown that Dex delivered
immediately after microdialysis probe insertion is capable of shifting macrophages to a more
+

+

CD68 CD163 state, the former M2c designation [34]. However, there is a body of literature suggesting
that an initial inflammatory response is critical for proper wound healing [35]. Therefore, we sought to
determine if a different or even more optimal response in terms of converting macrophages to an M(Dex)
state can be gained if the start of Dex infusion is delayed to allow the initial inflammatory response to
commence. The resulting foreign body reaction to the implanted dialysis probes was characterized not
only with standard histological means, but also immunohistochemical and molecular means at the gene
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and protein level. Thus, this work aimed to gain a better molecular understanding of macrophageactivation modulators effectiveness at controlling the foreign body reaction.

2. Results

3.1 qRT-PCR

Figure 1 shows the gene expression ratios of eleven different genes: Arginase (Arg2), CCL2,
CD163, CD206, Interleukin-1 receptor antagonist (IL-1ra), IL-6, IL-10, iNOS2, Lipocortin-1 (Lipo-1), TGFβ1, and TNF-α. Gene expression ratios were determined from tissue excised from around the
microdialysis probe using qRT-PCR. IL-6, CCL2, IL-1ra, IL-10, Lipo-1, TGF-β1, and TNF-α were chosen
to determine if delayed Dex was able to alter the cytokines involved in the FBR at the gene level. IL-6
was found to be significantly up-regulated in response to delayed Dex treatment. CCL2, IL-1ra, IL-10,
Lipo-1, TGF-β1, and TNF-α were not affected by delayed Dex treatment. Arg2, CD163, CD206, and
iNOS2 were chosen to determine if Dex had any effect on indicators of macrophage activation state at the
gene level and none of these were affected by delayed Dex treatment.
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Fig. 1. Relative gene expression ratios between treatment and
control tissue. Tissue samples from around the microdialysis probe
were used to determine relative gene expression ratios of eleven
different genes in response to delayed dexamethasone-21-phosphate
(20 µg/mL) treatment. (n=3) **p≤0.001 Error bars represent SEM.
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2.2 CCL2 Quantification

CCL2 concentrations were quantified in the dialysates collected from both control and treatment
probes for each hour of the six hour collection period as well as the initial flush (Figures 2-5). Three days
post implantation (Figure 2), CCL2 concentrations were found to be highest in both the control and
treatment dialysates during the initial flush with concentrations of ~1500 pg/mL and ~1700 pg/mL,
respectively. After the initial flush, CCL2 concentrations in the control dialysate dropped to ~900 pg/mL
during the first hour of collection and remained within ~200 pg/mL of that concentration for the entirety of
the collection period. In the treatment dialysate, CCL2 concentrations remained high, ~2000 pg/mL,
during the first hour of collection and then began to decrease over the remainder of the collection period
with concentrations being ~450 pg/mL during the last hour of collection. No significant difference in CCL2
concentrations was seen in the treatment as compared to the control in any of the time points tested at
three days post implantation.
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Fig. 2. Concentration of CCL2 3 days post implantation. Bar
graphs showing the concentration of CCL2 collected in
control and treatment dialysates. n=8 where n represents the
number of animals, *p≤0.05 with the error bars representing
the SEM, F represents the initial flush.
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Four days post implantation (Figure 3), CCL2 concentrations were found to be the highest during
the initial flush at ~2750 pg/mL and ~2000 pg/mL for control and treatment, respectively. After the initial
flush, CCL2 concentrations in the control dialysate dropped and remained relatively constant, fluctuating
from a high of ~1500 pg/mL to a low of ~1000 pg/mL. In the treatment dialysate, CCL2 concentrations
dropped during the first hour of collection to ~1500 pg/mL. Interestingly, a spike in CCL2 concentration
was seen during the second hour of collection in the treatment dialysate with values being the same as
was seen in the initial flush, ~2000 pg/mL. In hour 3, the concentration of CCL2 in the treatment dialysate
fell to ~450 pg/mL and was found to be significantly lower than the concentration of CCL2 in the control
dialysate. The concentration of CCL2 remained constant during hour 4 and showed a slight decrease in
hours 5 and 6 with CCL2 concentrations being significantly lower in the treatment dialysates as compared
to the control in hours 5 and 6.
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Fig. 3. Concentration of CCL2 4 days post implantation. Bar graphs
showing the concentration of CCL2 collected in control and
treatment dialysates. n=8 where n represents the number of
animals, *p≤0.05 with the error bars representing the SEM, F
represents the initial flush.
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Five days post implantation (Figure 4), CCL2 concentrations were again found to be highest in
the initial flush. After the initial flush, CCL2 concentrations reduced and were found to be relatively stable
over hours 1-6 ranging from ~1900 pg/mL to ~1200 pg/mL. In the treatment dialysate, CCL2
concentrations were found to steadily decrease from hours 1-6, ranging from ~1300 pg/mL to ~200
pg/mL. In hours 3-6, the concentration of CCL2 was found to be significantly lower in the treatment
dialysate as compared to the control dialysate.
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Fig. 4. Concentration of CCL2 5 days post implantation.
Bar graphs showing the concentration of CCL2 collected in
control and treatment dialysates. n=8 where n represents
the number of animals, *p≤0.05 with the error bars
representing the SEM, F represents the initial flush.
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Six days post implantation (Figure 5), CCL2 concentrations were found to be ~2400 pg/mL and
~2100 pg/mL in the control and treatment dialysates during the initial flush, respectively. During hours 16, CCL2 concentrations remained fairly constant at ~1500 pg/mL with a range of ~1750 pg/mL - ~1300
pg/mL in the control dialysate. In the treatment dialysate, CCL2 concentrations were found to steadily
decrease over the collection period from ~1350 pg/mL during hour 1 to ~500 pg/mL during hour six.
Though CCL2 concentrations were seen to decrease over time in the treatment dialysate, significance
was not reached in any of the collection periods tested.
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Fig. 5. Concentration of CCL2 5 days post implantation.
Bar graphs showing the concentration of CCL2 collected in
control and treatment dialysates. n=6 where n represents
the number of animals, *p≤0.05 with the error bars
representing the SEM, F represents the initial flush.
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2.3 Immunohistochemistry

Immunohistochemistry was used to investigate the density and number of total macrophages
+

+

+

(CD68 ) compared with M(Dex) macrophages (CD68 CD163 ) present in the tissue surrounding both
control and treatment microdialysis probes. At lower magnifications (Figure 6A) few macrophages are
seen surrounding the microdialysis probe in the control tissue. Further, there are minimal M(Dex),
+

+

CD68 CD163 ,macrophages seen with none seen less than 100 µm away from the microdialysis probe.
In the tissue surrounding the treatment probe, at lower magnification, many macrophages are seen
surrounding the probe with a high number of M(Dex) macrophages being present. At higher
magnification (Figure 6B), few M(Dex) macrophages are seen in the tissue immediately surrounding the
control probe. In the tissue surrounding the treatment probe, M(Dex) macrophages are seen immediately
surrounding the probe with M(Dex) macrophages seen as close as 30 µm away from the membrane. The
percent of M(Dex) macrophages found in the tissue surrounding both the control and treatment probes
+

was determined via manual counts of macrophages staining CD68 as well as macrophages staining
+

+

CD68 CD163 in the high magnification (40x) images (Figure 6C). The percentage of M(Dex)
macrophages found in the tissue surrounding the treatment probe was statistically higher than the
percentage of M(Dex) macrophages found in the tissue surrounding the control probe (Figure 7).
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Fig. 6. Immunohistochemical staining of tissue surrounding a microdialysis probe.
+
+
Immunohistochemistry was used to identify CD68 (green) cells, CD163 (red) cells, and
nuclei (blue). Cells which show an overlap of colors (stain both red and green or
yellow/orange) represent a M(Dex) macrophage. A) Tissue surrounding both control and
treatment microdialysis probes at 20X magnification. B) Tissue surrounding both control and
treatment microdialysis probes at 40X magnification. M indicates the microdiaylsis probe
membrane. Scale bars in lower right of each image represent 100 µm (20X) and 50 µm (40X).
Images representative of three animals.
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Fig. 7. Percent of CD68 Macrophages which Stain
+
+
CD68 CD163 [M (Dex)] macrophages surrounding a
microdialysis probe. Bar graph representing the percentage of
M(Dex) macrophages found in the tissue surrounding both the
control and treatment probe. Error bars represent the SEM
where *p≤0.01, n=12 where n represents the number of
measurements taken.
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2.4 Histology

Figure 8 shows the hematoxylin and eosin (H&E) and Masson's Trichrome analyses performed to
determine the effects of delayed Dex infusion on the cellular density and collagen in the tissue
surrounding the microdialysis probe seven days post-implantation. The tissue surrounding the treatment
probes was characterized as having a higher cellular density as well as more macrophages as compared
to the control probe. Further, the tissue is better integrated surrounding the treatment probe as compared
to the control as evidenced by the lack of acellular cytoplasmic material surrounding the treatment probe
which is seen in the control. Of the cells seen surrounding the control probe, there was a higher number
of foreign body giant cells as compared to the treatment probe. The Masson's Trichrome showed there to
be no appreciable difference in the amount of collagen seen in the tissue surrounding the treatment probe
as compared to the control probe. Additionally, for both the control and treatment probes, few aggregated
cells or foreign body giant cells were observed.
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Fig. 8. Histological staining of tissue surrounding a microdialysis probe. Top: H&E Stained
tissue (Six panes) (nuclei-blue, eosinophilic structures-red, basophilic structures-purple,
erythrocytes-bright red). Bottom: Masson’s Trichrome stained tissue (Six panes) (nuclei-dark
brown/black, cytoplasm-pink/light red, collagen-blue) A) Control and treatment tissue
immediately surrounding a microdialysis probe, 10X magnification, 100 µm scale. B) Control
and treatment tissue distal to the microdialysis probe, 10X magnification, 100µm scale. C)
Control and treatment tissue immediately surrounding a microdialysis probe, 40X magnification,
20µm scale bar. Images representative of three animals. M represents the microdialysis probe
membrane or tissue at the membrane interface.
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3. Discussion

Macrophages have long been recognized as pivotal cells for directing the foreign body reaction to
implanted biomaterials [4]. Within the biomaterials community, there is a tremendous interest in
modulating macrophage phenotype from what has been termed the M1, inflammatory phenotype, to the
anti-inflammatory, M2, phenotype [12]. In order for wounds to heal properly, there are multiple stages
through which a healing wound must pass [35]. In these stages, macrophages play many significant
roles and removal of macrophages is detrimental to wound healing [39]. Early in the wound stage,
macrophages release cytokines that attract additional leukocytes. Macrophages also clear neutrophils
from the site allowing for the resolution of inflammation. It is believed that during this stage, macrophages
can begin to alter their phenotype to a reparative state stimulating tissue regeneration [5, 40]. Within this
macrophage phenotype continuum at the host/biomaterial implant interface, there is an approximate
three- to five-day window before the arrival of fibroblasts that begin to deposit collagen [41]. In this study,
we chose to target altering macrophage phenotype within this approximate five-day window. While much
work has been done to understand the different activation states of macrophages in vitro, understanding
how shifts in macrophage activation states occurs in vivo is still lacking. Indeed, a review of many
different studies aimed to affect or knockout different cells involved in wound repair concludes that no one
cell type appears to be absolutely essential for repair, but inflammation is known to inhibit repair
processes by either slowing down the process or causing excessive fibrosis [42].
Dexamethasone is a synthetic glucocorticoid known to have powerful anti-inflammatory and
immunosuppressive effects. Dex has been widely used as a controlled-release agent in many different
biomaterials studies as a means to dampen the fibrotic response [33, 43-46]. Macrophages possessing
+

the M2c characteristic phenotype (CD163 ) have been implicated as being positive for appropriate tissue
remodeling at an implant site [47, 48]. Shifting macrophages to the M(Dex) (M2c) activation state has
become of interest in the field of biomaterials as it is thought that by doing so, the biomaterial will better
integrate into the surrounding tissue leading to reduced fibrosis, reduced scarring, and increased
longevity of some biomaterials. Dexamethasone is known to be able to shift macrophages to an M2c
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activation state [7, 10]. This M2c [M(Dex)] characteristic phenotype has been shown to result in the
increased expression of CD163 at the cell surface [49]. Additionally, since little is known about the timecourse or optimum timing necessary for altering macrophage activation, we chose to investigate a 3-day
post-implantation time for initiating Dex infusion. Others have suggested that immediate intervention to
the wound healing response may not be the most effective way to control the FBR as interfering with
normal wound healing processes leads to improper healing [50]. Following this rationale, allowing
macrophages to enter the wound site prior to attempting to modulate their phenotype may prove to be
more effective in long-term reduced fibrosis, reduction in fibrotic capsule, and better integration of the
biomaterial.
Delayed delivery of dexamethasone from the microdialysis probe resulted in the significant
increase of IL-6 at the gene transcript level. Similarly, we showed in a previous study that immediate and
daily infusion of Dex to a subcutaneous wound site in rats, resulted in the significant decrease in IL-6
gene transcription [34]. It should also be noted that IL-6 is known to exhibit either pro- and antiinflammatory properties [51]. While this finding was unexpected, it may be due to the delayed delivery of
Dex to the wound site. Additionally, while Dex has been widely used in biomaterials studies in the rat,
direct measurements of cytokine gene or protein expression are lacking in the literature.
The delayed delivery of Dex to the wound site had no effect on the transcription levels of the
remaining genes tested. In the cases of TNF-α and TGF-β1, these results are not surprising as TNF-α
levels have been shown to immediately rise following Dex administration [52] and the effects of Dex on
TGF-β1 have been shown to be highly variable [53-55]. These results were unexpected in the case of
CCL2 which has been shown to be decreased in response to Dex in a rat pancreatitis model [56], and in
response to locally delivered Dex to the subcutaneous space [34]. The inability of Dex to down-regulate
CCL2 gene transcription may be due to the delayed delivery of the Dex, the concentration of the Dex
delivered being insufficient to reduce CCL2, or a combination of the two. Further, this may be due to Dex
being able to decrease CCL2 mRNA stability as opposed to transcription rates as has been shown in vitro
[57].
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In the case of IL-1ra, Dex has been shown to decrease transcript levels in vitro in human
monocytes [58, 59]. Lipocortin-1 transcript levels have been shown to increase in response to
dexamethasone treatment in vitro in rat astrocytoma cells [60]. In this study, no difference in the
expression levels of IL-1ra or lipocortin-1 transcripts was observed. This may be due to the time course
of the study in which tissue was harvested after four days of Dex infusion. In the case of lipocortin-1,
previous up-regulation in gene transcription was seen four hours after Dex administration [60]. This might
imply that the effects of Dex on transcript levels had already peaked and returned to basal levels at the
time of tissue harvesting in this work. However, since direct protein concentration measurements were
not performed, it is not possible to say if Dex had any effect on their concentrations.
The transcription levels of Arg2, CD163, CD206, and iNOS2 were chosen as markers of
macrophage activation state. In M2c macrophages, protein levels of Arg2, CD163, and CD206 are
increased while iNOS2 is decreased. Although there was no differential expression of these transcripts,
this does not mean that there is no differential expression of the protein as it has been shown that
transcript levels and protein levels are poorly correlated [61]. The immunohistochemical analyses show
there to be an increase in the amount of CD163 protein present in response to Dex treatment. Since
protein levels for Arg2, CD206, or iNOS2 were not measured in this study, it is inconclusive whether
delayed delivery of Dex had an effect on their expression. Again, these differences may be due in part to
the timing where CD163 transcript levels may have peaked prior to tissue harvest.
CCL2 is a chemokine responsible for the recruitment of monocytes to a wound site. This cytokine
has been implicated as playing a significant role in wound repair and has recently been implicated in
promoting healing in diabetic wounds by restoring macrophage response [62]. However, in other work,
CCL2 knock-out mice have demonstrated an inability to form a fibrous capsule around implants [63]. In a
previous study, when Dex was immediately infused through the dialysis probe, the concentration of CCL2
was decreased roughly three hours after infusion initiation [34]. However, this effect was not immediately
apparent with the delayed Dex infusions. Here, the reduction in CCL2 concentrations was not altered
until the second day (four days post implant) of Dex infusion. Additionally, the reduction in CCL2
concentration was also not as great as with immediate Dex infusion. Moreover, while some reductions in
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CCL2 concentrations were observed on the third day of infusion (5 day post-implantation), no significant
th

alterations in CCL2 concentrations are observed on the fourth day (6 day post-implantation) of Dex
infusion. While in all cases, the CCL2 concentrations decrease after initiation of the dialysis collection,
what is notable is the initial collected concentrations in the flush collection. While many microdialysis
sampling practitioners would generally not even analyze initial flush solutions through the probe, this is
actually fluid that may be more representative of the approximate external concentrations residing in the
extracellular fluid space (ECS) in the tissue in contact with the dialysis probe. The dead volume within
the dialysis probe shaft is roughly 1 µL. However, if solutes diffuse into the shaft, they can continue to
diffuse through the tubing lines. While these initial flush concentrations were variable from day to day, the
average is roughly 2000 to 2500 pg/mL. The decreasing concentrations of CCL2 after initiation of dialysis
indicate that CCL2 production in the ECS is not sufficient to compete with the dialysis removal process.
However, the significant decrease in CCL2 with Dex-delivery in some days suggests bioactivity of the Dex
at the tissue site. Why this decrease in CCL2 is not as significant as with the daily infusions of Dex that
we have previously reported is not clear. The lack of difference in CCL2 concentrations between control
and treatment six days post implantation may suggest that after three days of Dex infusion, higher
concentrations of Dex are needed to illicit the same effect. This may also be due to the arrival of more
CCL2-secreting cells, such as macrophages, to the tissue surrounding the treatment probe, as is seen in
the histological analyses. These macrophages may be receiving competing endogenous signals from
within the extracellular space such that addition of Dex does not effectively modulate the CCL2 levels.
Immunohistochemical analyses were performed to determine the effects of delayed Dex infusion
+

on the amount of macrophages (CD68 ) present in the tissue surrounding the microdialysis probe as well
+

+

as the amount of M(Dex) (CD68 CD163 ) macrophages present. The interesting finding here is that
+

+

CD68 CD163 macrophages are not found adjacent to the dialysis probe, but rather further away (~100
µm in control tissue and ~30 µm in treatment tissue). This is consistent with a recent scaffold implant
study in rats that measured CD68 and CD206 (a pan M2 macrophage marker), but not CD163, where
+

+

+

they observed CD68 cells near the scaffold/tissue interface and CD68 CD206 cells farther away [64].
While these findings are consistent, we note that CD206 was not quantified in this study. While all M2
macrophages would be expected to express CD206, we have not stained for this marker in this work and
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+

thus cannot say if this would hold true in this work. More importantly, CD68 CD163 macrophages are
observed in both control and treatment tissue, but with more M(Dex) macrophages at the treatment site.
This suggests that while the biomaterial itself may result in the previously described M2c activation state
+

+

(CD68 CD163 ), it is clear that adding Dex appears to promote a significantly higher wound healing
macrophage phenotype. Additionally, few foreign body giant cells were observed in this study which is
consistent with a recent non-degradable implant study in the rat [65].
Dexamethasone has been previously used extensively in biomaterials studies in an effort to
reduce fibrosis where histological analyses were used as an endpoint [44-46, 66]. These studies have
shown that tissue surrounding dexamethasone eluting materials are characterized as having reduced
cellular density. We have previously reported that immediate infusion of Dex results in a loose capsule
surrounding the dialysis probe resulting in difficulties in obtaining the tissue for histological analysis [34,
67]. However, with delayed Dex infusion, the results demonstrated an increased cellular density
surrounding the treatment probe as compared to the control probe. Further, we found no difference in the
amount of collagen present in the tissue surrounding the treatment probe as compared to the control
probe. These differences may be attributed to three factors: 1) initial burst associated with other
techniques, 2) the time course of Dex infusion, 3) the concentration of Dex used. While many controlled
release biomaterials suffer from initial bursts of drug (dexamethasone), the microdialysis sampling
approach allows a constant (zero-order) delivery of Dex. Further, controlled release biomaterials begin
eluting drug immediately following implantation (the initial burst) and continuously deliver the drug over
time. Our technique allows for the delivery of Dex for defined amounts of time with the ability to begin
delivery at any given time post implantation. This is important due to increasing knowledge that an initial
wounding response is necessary to elicit appropriate wound healing [35, 50]. Finally, the concentrations
of Dex used in this study differ from the previously mentioned studies. In the previously mentioned
studies, a concentration range from 5.3 µg-7 mg of Dex was used. In this work, ~3.6 µg of Dex was
delivered per six hour collection period resulting in a total of ~14.4 µg of Dex being delivered over the
entire collection period. It should be noted at this point that the ~14.4 µg of Dex does not take into
account the Dex which was allowed to remain in the probe and freely diffuse out between collection
periods. While our previous study showed ~10.6 µg of Dex to be sufficient to reduce cellular density
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around the treatment probe, this was in response to immediate Dex delivery following implantation [34]
while in this study Dex was not delivered until three days post implantation. To our knowledge, this is the
first study to look at the effects of delayed Dex infusion on a subcutaneous implant site. An additional
concern is that we do not know the range of Dex actually needed to induce macrophages to the
+

+

CD68 CD163 state.

4. Conclusions

In this study, microdialysis sampling probes were implanted in the subcutaneous space of rats
and used to locally deliver Dex over a four day period starting three days post probe implantation. The
delayed delivery of Dex resulted in an up-regulation of IL-6 gene transcripts as well as a moderate
decrease in collected CCL2 concentrations. Histologically, the delayed Dex treatment resulted in an
increase in cellular density in the tissue surrounding the microdialysis probe. Further, the delayed
+

+

delivery of Dex was able to shift macrophages to an M(Dex) activation state (CD68 CD163 macrophages
(M2c) in the tissue). The use of modulators to shift the activation state of macrophages has focused
primarily on in vitro studies. This is the first study to show that a delayed delivery of Dex can be used to
shift macrophages to an M(Dex) activation state in vivo at a non-degradable implant site.
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Conclusion
The work presented in this dissertation focused on switching the activation state of macrophages
to a predominantly M2c state at a non-degradable implant site via microdialysis sampling technique.
While microdialysis sampling has many characteristics which make it an ideal technique for this work,
colloids must be used to prevent ultrafiltration, the loss of fluid across the microdialysis membrane, when
using high MWCO membranes. Initially perfusion fluids contained Dextran-70, a commonly used colloid.
However, increased inflammation was seen at the implant site. After a series of experiments, it was
determined that this increase in inflammation was due to the diffusion of Dextran-70 across the
microdialysis membrane, allowing the Dextran-70 to enter the extracellular space. Upon further
investigation, a suitable perfusion fluid which resulted in no additional inflammation at the implant site was
discovered. The replacement of Dextran-70 with Dextran-500 proved to be acceptable as Dextran-500
successfully limited ultrafiltration while resulting in no increased inflammation at the implant site.
Once a suitable perfusion fluid was found, Dex was delivered to the implant site immediately
following implantation via the microdialysis probe in an attempt to shift the activation state of
macrophages to a predominantly M(Dex) state. At the gene level, the immediate administration of Dex
resulted in the significant down-regulation of both CCL2 and IL-6 in the tissue surrounding the treatment
probe as compared to the control probe. Immediate Dex infusion also resulted in the significant decrease
of CCL2 concentration collected in the treatment dialysate as compared to the control dialysate.
Histologically, Dex resulted in mostly unusable treatment sections which may have been due to the
decrease in cellular density seen in the tissue surrounding the treatment probe as compared to the
control probe, where sections were obtained. Most importantly, as it was the main aim, Dex resulted in a
significant increase in the percentage of M(Dex) macrophages in the tissue surrounding the treatment
probe as compared to the control probe. This showed that it is possible to use modulators to alter the
activation state of macrophages at a non-degradable implant site.
Once it was determined that Dex could be used to alter macrophage activation states, in vivo I set
out to determine if a different/more optimal response could be garnered from the delayed delivery of Dex
to the implant site. For this work, Dex was not administered until three days post implantation. This time
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point allows for the initial inflammatory response to occur. The delayed delivery of Dex gave results
which were similar yet very different from what was seen in response to immediate Dex infusion. At the
gene level, it was found that IL-6 was significantly increased in the tissue surrounding the treatment probe
as compared to the control. This result differs from what was seen in response to the immediate delivery
of Dex. At the protein level, delayed Dex administration also resulted in the significant decrease in CCL2
concentrations collected from treatment dialysates as compared to control dialysates. However, the
response seen in the delayed delivery varied greatly from what was seen in response to the immediate
infusion and was seen to be much more transient. Histologically, an increase in cellular density was seen
in the tissue surrounding the treatment probe as compared to the control which is in stark contrast to what
was seen in response to immediate Dex delivery. Immunohistochemically, Dex proved to be able to
significantly increase the percentage of M(Dex) macrophages in the tissue surrounding the treatment
+

probe as compared to the control. Interestingly, roughly the same percentage of CD68 CD163

+

macrophages were seen in the tissue surrounding the treatment probes in both the delayed and
immediate Dex delivery experiments (~65%). However, a greater number of macrophages (both
+

-

+

+

CD68 CD163 and CD68 CD163 ) were seen in the delayed Dex experiment as compared to the
immediate Dex experiment, suggesting that this time point allows for a more predominantly macrophage
response to be targeted as compared to the immediate Dex delivery.
This work shows that it is possible to use modulators to shift macrophages to a predominantly
M(Dex) activation state at a non-degradable implant site while giving a better understanding of what is
happening at the molecular level.. Further, it shows that differential effects are seen in response to the
immediate and delayed delivery of Dex to the implant site. While much work has been done on
understanding macrophage activation, most of this work was done in vitro. Understanding how in vitro
modulators may affect macrophages in vivo as well as characterizing this response may lead to increased
longevity and improved integration/healing of biomaterials and their wound sites in the future. At this
point, experiments where Dex is delivered both immediately and at 3 days post implantation with 14+ day
end points are needed. These experiments will determine if the initial effects of the Dex are maintained
and if there are any differences in integration and healing. Further, it is important to study other
modulators which may be used to shift macrophages to an M2c activation state as well as characterize
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the molecular response associated with these modulators. Through this work it may be possible to
improve the integration of biomaterials into host tissue as well as increase longevity while reducing failure
rates.
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Appendix A

Effects of IL-10 Delivery at a Non-Degradable Implant Site on Macrophage Activation State via
Microdialysis Sampling in Rats
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1. Introduction

In today's society, implanted biomaterials have become common place with the use of such
things as prostheses, heart valves, artificial breasts, and biosensors. The foreign body response (FBR) is
the body's response to the implantation of most biomaterials. This response is characterized initially by
acute inflammation at the wound site and eventual encapsulation of the biomaterial causing the
biomaterial to reside in its own microenvironment. While this encapsulation poses no threat to many
biomaterials, e.g. artificial breasts, artificial knees, screws, the encapsulation is detrimental to other
biomaterials which rely on proper communication with the extracellular space (ECS), e.g. biosensors. In
fact, the encapsulation of these biomaterials results in their inability to be used after seven days in vivo.
Controlling or altering the FBR would lead to better integration of all biomaterials into the host tissue as
well as possibly increasing the longevity of many biomaterials such as biosensors.
Interleukin-10 is a homodimeric cytokine with each dimer ranging in size from 17 - 18 kDa [1, 2].
IL-10 is known to be a potent anti-inflammatory cytokine which reduces levels of pro-inflammatory
cytokines such as IL-1, IL-6, IL-12, and TNF-α as well as reducing the expression of major
histocompatibility complex II (MHC II) [3]. IL-10 has also been shown to affect chemokine (C-C motif)
ligand 2 (CCL2) but reports are conflicting as to whether CCL2 is increased or decreased in response to
IL-10 [4-6]. Interleukin-1 receptor antagonist has been shown to be increased in response to IL-10
adding to the anti-inflammatory effects [3]. The exact mechanisms through which IL-10 exerts its' antiinflammatory effects are unknown but it is thought to alter nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) [3], and mitogen-activated protein kinase (MAPK) signaling pathways [7], as
well as activating suppressor of cytokine signaling 3 (SOCS3) which has regulatory effects on many
cytokine genes [3, 8, 9]. Recently, a viral vector was used to deliver IL-10 at a scaffold implant in mice
resulting in reduced leukocyte infiltration of the scaffold, reduced IFN-γ production, and increased IL-10
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production [10]. Interleukin-10 shows promise as a modulator in the field of biomaterials due to the antiinflammatory effects as well as IL-10's ability to induce M2c macrophages.
The focus of this work is to use microdialysis sampling probes to locally deliver IL-10 to a wound
site. IL-10 was chosen due to its ability to shift macrophages to an anti-inflammatory, pro-wound healing,
pro-tissue remodeling activation state. To determine the effects of IL-10 on the wound site, cytokine
responses (primarily CCL2) were investigated as well as histological and immunohistochemical analyses.

2 Results

2.1 IL-10 (10 ng/mL) Perfusion (Dextran-70)

Figure 1 shows a box plot of the concentration of CCL2 in dialysates collected from a control
probe and a treatment probe which had 10 ng/mL IL-10 added to the perfusion fluid. CCL2
concentrations rose steadily over the collection period in the dialysates of both the control and treatment
probes. In the first hour of collection, the average CCL2 concentration was slightly higher in the control
dialysate as compared to the treatment dialysate at ~800 pg/mL as compared to ~500 pg/mL
respectively. Over the following 6 hours, CCL2 concentrations were found to be higher in the treatment
dialysate as compared to the control dialysate. At the end of the collection period, hour 7, the average
CCL2 in the control dialysate was ~6200 pg/mL while the average CCL2 concentration in the treatment
dialysate was ~9500 pg/mL. While a trend was seen where CCL2 concentrations were higher in the
treatment dialysate as compared to control dialysates, there was no statistical difference between these
values at a 95% confidence interval.
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Fig. 1. Box plot showing concentration of CCL2 collected in control and treatment (10
ng/mL IL-10) dialysates over a 7 hour period on the day of implantation.
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Figure 2 shows images of hematoxyllin and eosin (H&E) and Masson's Trichrome stained tissue
surrounding a control probe and a 10 ng/mL IL-10 treatment probe. These two stains are used to identify
cells (H&E) and collagen (Masson's Trichrome). The H&E stain shows that the cells surrounding the
treatment probe are slightly more densely packed than the cells surrounding the control probe. The
Masson's Trichrome stained sections, show no appreciable difference in the amount of collagen
surrounding the control and treatment probes. Further, there is no appreciable difference in the
organization of the collagen or in the collagen strand thickness surrounding the control and treatment
probes.
Immunohistochemistry was used to determine the effect IL-10 had on the phenotype of
macrophages found in the tissue surrounding the microdialysis probe. To identify macrophages, an
antibody specific for CD68 was used. To determine if more M (IL-10) macrophages (formerly known as
M2c macrophages) were found surrounding the treatment probe as compared to the control probe, an
antibody specific for CD163 was used. Further, antibodies specific for CCR7 and CD206 were used to
determine the effects of IL-10 infusion on the amount of M1 and M2 macrophages found in the tissue
surrounding the microdialysis probe, respectively. There was no appreciable difference in the amount of
macrophages surrounding the treatment probe as compared to the control probe (Fig 3 A&B). Further,
there was no appreciable difference in the phenotype of macrophages surrounding the treatment probe
as compared to the control probe, that is, there was no difference in the number of cells staining
+

+

+

CCR7 (Fig 3 C&D), CD206 (Fig 4 A&B), or CD163 (Fig 4 C&D). Interestingly though, there appeared to
+

+

be more cells which stained both CD206 and CD163 in both tissues than there were cells that stained
+

CD 68 .
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Fig. 2. Control vs. 10 ng/mL IL-10 treated probe. Top: H&E stain (A) Microdialysis probe
implanted in the subcutaneous space utilizing a control perfusion fluid. (B) Microdialysis probe
implanted in the subcutaneous space utilizing a treatment (10 ng/mL IL-10) perfusion fluid.
Bottom: Masson's Trichrome stain. (C) Microdialysis probe implanted in the subcutaneous
space utilizing a control perfusion fluid. (D) Microdialysis probe implanted in the subcutaneous
space utilizing a treatment (10 ng/mL IL-10) perfusion fluid. 10x magnification, white bar
represents 100 µm.
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+

+

+

Fig. 3. Immunohistochemistry for CD68 and CCR7 macrophages. Left: CD68
+
macrophages present around the microdialysis probe. Right: CCR7 macrophages
present around the microdialysis probe. Top: Tissue surrounding a microdialysis probe
implanted subcutaneously which utilizes a control perfusion fluid. Bottom: Tissue
surrounding a microdialysis probe implanted subcutaneously which utilizes a treatment
(10 ng/mL IL-10) perfusion fluid. 20x magnification, paraffin embedded sections.
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(C)

(A)

(B)

(D)
+
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+

Fig. 4. Immunohistochemistry for CD206 and CD163 macrophages. Left: CD206
+
macrophages present around the microdialysis probe. Right: CD163 macrophages
present around the microdialysis probe. Top: Tissue surrounding a microdialysis
probe implanted subcutaneously which utilizes a control perfusion fluid. Bottom:
Tissue surrounding a microdialysis probe implanted subcutaneously which utilizes a
treatment (10 ng/mL IL-10) perfusion fluid. 20x magnification, paraffin embedded
sections.
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2.2 IL-10 Ultrafiltration (Dextran-70)

CCL2 concentrations were measured in the dialysates of control and treatment (10 ng/mL IL-10)
probes. Figure 5 shows a box plot of the concentrations of CCL2 collected in both the control and
treatment dialysates over the 7 hour collection period. In the first hour of collection, concentrations of
CCL2 were approximately the same in the control and treatment dialysates. Over the 7 hour collection
period, the concentration of CCL2 steadily rose in the dialysates of the control probes. In the dialysates
from the control probes, average CCL2 concentrations ranged from ~ 500 pg/mL during the first hour of
collection to ~5500 pg/mL during the final hour of collection. In the dialysates collected from the
treatment probes, average CCL2 concentrations ranged from ~500 pg/mL in the first hour of collection to
~5800 pg/mL during the final hour of collection. While the average concentration of CCL2 collected from
the treatment probe increased over the collection period, there was no steady increase seen in CCL2
concentration as was seen in the dialysates collected from the control probes. In fact, the concentration
range of CCL2 collected in the dialysates of treatment probes peaked during the second hour of collection
with no difference seen between the second hour and the following hours.
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Fig. 5. Box plot showing concentration of CCL2 collected in control and
treatment (10 ng/mL IL-10) dialysates over a 7 hour period on the day of
implantation in response to ultrafiltration.
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Histological studies were performed to determine the effects of IL-10 ultrafiltration on the
morphology of the tissue surrounding the microdialysis probe. H&E stains were performed to determine
the cellular density of the tissue surrounding the probes as well as the organization of cells in the tissue
surrounding the probes. In the IL-10 ultrafiltration tissue, the cells were less densely packed in the tissue
surrounding the probe as compared to the tissue surrounding the control probe (Fig 6 A&B). There also
appears to be more cells interrogating the control probe membrane as compared to the treatment probe
membrane. Further, the tissue around the control probe is more organized than that surrounding the
treatment probe. Masson's Trichrome stain was performed to investigate the amount of collagen present
in the tissue surrounding the probes as well as the strand thickness and organization of the collagen. The
Masson's Trichrome stained tissues show there to be more collagen in the tissue surrounding the
treatment probe as compared to the control probe (Fig 6 C&D). Further, the collagen is well organized
and seen much closer, to the treatment probe, immediately surrounding, as compared to the control
probe, ~150 µm before significant amounts of collagen are seen. Interestingly though, the tissue
surrounding the treatment probe is more vascular than the tissue seen surrounding the control probe
where practically no blood vessels are seen.
Immunohistochemistry was also performed to determine the amount of macrophages in the tissue
surrounding both the control and treatment probes as well as the predominant phenotype of these
+

macrophages. No appreciable difference was seen in the amount of macrophages (CD68 ) in the tissue
surrounding the probe. Further, there was no appreciable difference in the phenotype of the
+

+

macrophages. That is, there was no difference in the amount of CCR7 , CD206 , or CD163
macrophages.
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+

Fig. 6. Ultrafiltration of control and 10 ng/mL IL-10 treated probe. Top: H&E stain (A)
Microdialysis probe implanted in the subcutaneous space utilizing a control perfusion fluid
and ultrafiltration. (B) Microdialysis probe implanted in the subcutaneous space utilizing a
treatment (10 ng/mL IL-10) perfusion fluid and ultrafiltration. Bottom: Masson's Trichrome
stain. (C) Microdialysis probe implanted in the subcutaneous space utilizing a control
perfusion fluid and ultrafiltration. (D) Microdialysis probe implanted in the subcutaneous
space utilizing a treatment (10 ng/mL IL-10) perfusion fluid and ultrafiltration. 10x
magnification, white bar represents 100 µm.
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2.3 Four Day IL-10 Infusion (Dextran-70)

Collections were performed on the day of implantation and 4 days post implantation. The
concentration of seven different analytes were quantified each day: CCL2, IL-1β, IL-6, IL-10, KC/GRO,
MIP-2, and RANTES. Concentrations of the seven analytes were quantified in both control and treatment
(10 ng/mL IL-10) dialysates (Fig 7). On the day of implantation, CCL2 concentrations ranged from 15
pg/mL – 1795 pg/mL in control and from 20 pg/mL – 510 pg/mL in treatment, IL-1β concentrations ranged
from 15 pg/mL – 450 pg/mL in control and from below 5 pg/mL – 680 pg/mL in treatment, IL-6
concentrations ranged from below 75 pg/mL – 515 pg/mL in control and from below 75 pg/mL – 595
pg/mL in treatment, IL-10 concentrations ranged from 15 pg/mL – 1035 pg/mL in control and from below
10 pg/mL - 805 pg/mL in treatment, KC/GRO concentrations ranged from 15 pg/mL - 640 pg/mL in control
and from 5 pg/mL – 555 pg/mL in treatment, MIP-2 ranged from below 25 pg/mL - 1610 pg/mL in control
and from below 25 pg/mL – 415 pg/mL in treatment, and RANTES ranged from 15 pg/mL – 1170 pg/mL
in control and from 15 pg/mL – 510 pg/mL in treatment. Four days post implantation, CCL2 levels ranged
from below 10 pg/mL-3930 pg/mL in the control and from below 10 pg/mL-145 pg/mL in the treatment, IL1β concentrations ranged from 15 pg/mL -over 10,000 pg/mL in control and from 5 pg/mL- 155 pg/mL in
treatment, IL-6 concentrations ranged from below 75 pg/mL - over 300,000 pg/mL in control and from
below 75 pg/mL -165 pg/mL in treatment, IL-10 concentrations ranged from 15 pg/mL - 3620 pg/mL in
control and from 20 pg/mL-260 pg/mL in treatment, KC/GRO concentrations ranged from 15 pg/mL 15835 pg/mL in control and from 5 pg/mL – 260 pg/mL in treatment, MIP-2 ranged from below 25 pg/mL –
5550 pg/mL in control and from below 25 pg/mL - 210 pg/mL in treatment, and RANTES ranged from 10
pg/mL – 7830 pg/mL in control and from 15 pg/mL – 300 pg/mL in treatment. A significant difference
between control and treatment was found only in the concentration of IL-10 collected during the initial
flush four days post implantation.

159

Control
Treatment

Concentration of CCL2
Day of Implantation

700

300

Conc CCL2 (pg/mL)

Conc CCL2 (pg/mL)

600

Control
Treatment

Concentration of CCL2
Four Days Post Implantation

350

500
400
300
200
100

250
200
150
100
50

0

0
1

2

3

4

5

6

7

1

2

Hour of Collection

120

3

4

5

6

7

Hour of Collection

Concentration of IL-1β
Day of Implantation

Concentration of IL-1 β
Four Days Post Implantation

800

Control
Treatment

Control
Treatment

700

100

Conc IL-1β (pg/mL)

Conc IL-1β (pg/mL)

600
80

60

40

500
400
300
200

20

100
0

0
1

2

3

4

5

6

1

7

2

Concentration of IL-6
Day of Implantation

300

3

4

5

6

7

Collection Hour

Collection Hour

Concentration of IL-6
Four Days Post Implantation

450
Control
Treatment

Control
Treatment

400

250

Conc IL-6 (pg/mL)

Conc IL-6 (pg/mL)

350
200

150

100

300
250
200
150
100

50
50
0

0
1

2

3

4

5

6

1

7

2

3

4

5

Hour of Collection

Hour of Collection

160

6

7

Concentration of IL-10
Day of Implantation

Control
Treatment

8000

Control
Treatment

Concentraion of IL-10
Four Days Post Implantation

2500

6000

Conc IL-10 (pg/mL)

Conc IL-10 (pg/mL)

7000

5000
4000
3000

2000

1500

1000

*

2000
500
1000
0

0
1

2

3

4

5

6

7

1

2

Hour of Collection

1000

Concentration of KC/GRO
Day of Implantation

Control
Treatment

5

6

7

Control
Treatment

20

Conc KC/GRO (pg/mL)

Conc KC/GRO (pg/mL)

4

Concentration of KC/GRO
Four Days Post Implantation

800

600

400

200

0

15

10

5

0
1

2

3

4

5

6

7

1

2

Collection Hour

600

3

4

5

6

7

Collection Hour

Control
Treatment

Concentration of MIP-2
Day of Implantation

Concentration of MIP-2
Four Days Post Implantation

7000

Control
Treatment

6000

Conc MIP-2 (pg/mL)

500

Conc MIP-2 (pg/mL)

3

Hour of Collection

400

300

200

100

5000
4000
3000
2000
1000

0

0
1

2

3

4

5

6

7

1

Hour of Collection

2

3

4

5

Hour of Collection

161

6

7

Concentration of RANTES
Day of Impantation

40

Concentration of RANTES
Four Days Post Implantation

Control
Treatment

35
30

Conc RANTES (pg/mL)

Conc RANTES (pg/mL)

Control
Treatment

20

25
20
15
10

15

10

5

5
0

0
1

2

3

4

5

6

7

1

Hour of Collection

2

3

4

5

6

7

Hour of Collection

Fig. 7. Bar graphs showing the concentration of seven analytes in both control and
treatment (four day infusion of 10 ng/mL IL-10) dialysates. Collections were performed on
the day of implantation and four days post implantation. *p≤0.05
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Figure 8 shows histological results from tissue surrounding a control probe and tissue
surrounding a treatment probe where 10 ng/mL IL-10 was infused for four days. H&E stained tissue
shows a thin, ~50 µm or less, area of densely packed cells immediately surrounding the control probe
with the remaining tissue consisting of well-organized but more scattered cells. The tissue surrounding
the treatment probe consists of a larger area of densely packed cells surrounding the probe, ~100 µm or
more. Past the initial area of densely packed cells, cells are found to be scattered and not well organized.
The Masson's Trichrome stained tissue shows there to be more collagen surrounding the treatment probe
as compared to the control though this difference is negligible and may be due in part to the cells distal to
the probe in the control tissue being more organized therefore making the collagen seem more dispersed.
Interestingly, in the Masson's Trichrome stained tissue, a ring of tissue ~200 µm wide is present
immediately surrounding the treatment probe which is absent in the control tissue. This ring of tissue
consists of neutrophils, macrophages, foreign body giant cells, blood, and possibly cellular debris and
dead cells.
Immunohistochemistry was also performed on the tissue surrounding both the control and
treatment probes to determine if the treatment had any effect on the amount of macrophages present or
on the predominant macrophage activation state present. No appreciable difference was seen in the
+

amount of macrophages (CD68 ) surrounding the treatment probe as compared to the control probe.
+

+

+

Further, there was no difference in the amount of CCR7 , CD206 , or CD163 macrophages surrounding
the treatment probe as compared to the control probe.
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Fig. 8. Control and four day infused10 ng/mL IL-10 treated probe. Top: H&E stain (A )
Microdialysis probe implanted in the subcutaneous space utilizing a control perfusion fluid.
(B) Microdialysis probe implanted in the subcutaneous space utilizing a treatment (10
ng/mL IL-10) perfusion fluid infused for four days. Bottom: Masson's Trichrome stain (C)
Microdialysis probe implanted in the subcutaneous space utilizing a control perfusion fluid.
(D) Microdialysis probe implanted in the subcutaneous space utilizing a treatment (10
ng/mL IL-10) perfusion fluid infused for four days. 10x magnification, white bar represents
100 µm.
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2.4 IL-10: 200 and 1200 ng/mL Infusion (Dextran-500)

200 ng/mL Infusion

Histological analyses were performed to determine cellular density (H&E) and collagen presence
in the tissue surrounding a control probe and a treatment probe (200 ng/mL IL-10 infused). Figure 9
shows the H&E stained tissue. The tissue surrounding the control probe is well organized and densely
packed immediately surrounding the probe. This tissue remains well organized and densely packed in
areas as far as ~500 µm away from the probe. The tissue surrounding the treatment probe has a dense
ring of cells, ~100 µm, immediately surrounding the probe. Further, there is an area of tissue immediately
surrounding the probe consisting of neutrophils, macrophages, foreign body giant cells, blood, and
possibly cellular debris and dead cells, much like was seen in the tissue surrounding the four day IL-10
infused tissue only exacerbated. Interestingly, once past the initially dense ring of cells, the tissue is
found to be much less organized with cells being far more scattered in the treatment tissue as compared
to the control tissue. The Masson's Trichrome stained tissue shows collagen immediately surrounding
both the control and treatment probes (Fig 10). However, there appears to be more collagen immediately
surrounding the control probe as well as consisting of much thicker strands as compared to the treatment
probe. In areas more distal to the probe, the amount of collagen in the tissue increases in the tissue
surrounding the control probe with thick strands persisting throughout (Fig 10B). In the tissue
surrounding the treatment probe, very little collagen is found in areas distal to the probe (Fig 10D).
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Fig. 9. H&E stained control and 200 ng/mL IL-10 treated tissue. Left: Tissue immediately
surrounding the microdialysis probe. (A) Microdialysis probe implanted in the subcutaneous
space utilizing a control perfusion fluid. (B) Microdialysis probe implanted in the
subcutaneous space utilizing a treatment. (200 ng/mL IL-10) perfusion fluid. Right: Tissue
distal to the microdialysis probe. (C) Microdialysis probe implanted in the subcutaneous
space utilizing a control perfusion fluid. (D) Microdialysis probe implanted in the
subcutaneous space utilizing a treatment (200 ng/mL IL-10) perfusion fluid. 10x
magnification, white bar represents 100 µm.

166

Fig. 10. Masson's Trichrome stained control and 200 ng/mL IL-10 treated tissue. Left:
Tissue immediately surrounding the microdialysis probe. (A) Microdialysis probe implanted in
the subcutaneous space utilizing a control perfusion fluid. (B) Microdialysis probe implanted
in the subcutaneous space utilizing a treatment (200 ng/mL IL-10) perfusion fluid. Right:
Tissue distal to the microdialysis probe. (C) Microdialysis probe implanted in the
subcutaneous space utilizing a control perfusion fluid. (D) Microdialysis probe implanted in
the subcutaneous space utilizing a treatment (200 ng/mL IL-10) perfusion fluid. 10x
magnification, white bar represents 100 µm.
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Immunohistochemistry was performed to determine if there was any difference in the amount of
+

+

+

macrophages (CD68 ) or the predominant phenotype (CD206 and CD163 ) in the tissue surrounding the
IL-10 treated probe as compared to the control probe. Antibodies specific for rat CD68 were used to
identify macrophages in the tissue surrounding the microdialysis probe. Antibodies specific for CD206
and CD163 were used to identify M2 and M(IL-10) (M2c) macrophages in tissue surrounding the
+

microdialysls probe. No appreciable difference was seen in the number of macrophages (CD68 ) in the
tissue surrounding the treatment as compared to the control probe (Fig 11). Further, no difference was
+

seen in the amount of M2 (CD206 ) macrophages present in the tissue surrounding the treatment probe
+

as compared to the control probe (Fig 12). There seemed to be a slightly more CD163 [M(IL-10)]
macrophages in the tissue surrounding the treatment probe as compared to the control but this difference
is negligible (Fig 13).
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Fig. 11. Macrophages surrounding the microdialysis probe. These cells are preferentially stained
using antibodies specific for CD68. Top: Tissue surrounding a control microdialysis probe.
Bottom: Tissue surrounding a treatment (200 ng/mL IL-10) microdialysis probe. Images are 20X
magnification, paraffin embedded tissue.
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Fig. 12. M2 macrophages surrounding the microdialysis probe. These cells are preferentially
stained using antibodies specific for CD206. Top: Tissue surrounding a control microdialysis
probe. Bottom: Tissue surrounding a treatment (200 ng/mL IL-10) microdialysis probe. Images
are 20X magnification, paraffin embedded tissue.
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Fig. 13. M(IL-10) (M2c) macrophages surrounding the microdialysis probe. These cells are
preferentially stained using antibodies specific for CD163. Top: Tissue surrounding a control
microdialysis probe. Bottom: Tissue surrounding a treatment (200 ng/mL IL-10) microdialysis
probe. Images are 20X magnification, paraffin embedded tissue.
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1200 ng/mL IL-10 Infusion

Tissue surrounding both the control and treatment (1200 ng/mL IL-10) were stained using H&E
and Masson's Trichrome. Figure 14 shows H&E stained tissue surrounding both control and treatment
probes. In the tissue surrounding the control probe, a dense cellular layer, ~200 µm or greater, is seen
immediately surrounding the probe. Distal to this area, the tissue is well organized and cells are dense,
though not as densely packed as is seen immediately surrounding the probe. Immediately surrounding
the treatment probe, a highly dense area of cells is seen which stain dark purple to black representing
neutrophils, macrophages, foreign body giant cells, blood, and possibly cellular debris and dead cells.
This area is similar to what was seen in the 200 ng/mL treated IL-10 tissue. Immediately surrounding this
highly dense area, an area of tissue is seen which seems to be necrotic. However, beyond the necrotic
tissue, the cells are scattered and less well organized as compared to the control. Figure 15 shows
Masson's Trichrome stained tissue surrounding both control and treatment probes. In the tissue
surrounding the control probe, collagen is seen immediately surrounding the probe with increased
amounts of collagen seen in areas distal to the probe. In the treatment tissue, very little collagen is seen
in areas within the necrotic tissue with a ring of thick collagen seen surrounding the necrotic tissue.
Interestingly, distal to the necrotic tissue, less collagen is seen as compared to the control tissue.
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Fig. 14. H&E stained control and 1200 ng/mL IL-10 treated tissue. Left: Tissue
immediately surrounding the microdialysis probe. (A) Microdialysis probe implanted in the
subcutaneous space utilizing a control perfusion fluid. (B) Microdialysis probe implanted in
the subcutaneous space utilizing a treatment (1200 ng/mL IL-10) perfusion fluid. Right:
Tissue distal to the microdialysis probe. (C) Microdialysis probe implanted in the
subcutaneous space utilizing a control perfusion fluid. (D) Microdialysis probe implanted in
the subcutaneous space utilizing a treatment (1200 ng/mL IL-10) perfusion fluid. 10x
magnification, white bar represents 100 µm.
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Fig. 15. Masson's Trichrome stained control and 1200 ng/mL IL-10 treated tissue. Left:
Tissue immediately surrounding the microdialysis probe. (A) Microdialysis probe implanted in
the subcutaneous space utilizing a control perfusion fluid. (B) Microdialysis probe implanted in
the subcutaneous space utilizing a treatment (1200 ng/mL IL-10) perfusion fluid. Right:
Tissue distal to the microdialysis probe. (C) Microdialysis probe implanted in the
subcutaneous space utilizing a control perfusion fluid. (D) Microdialysis probe implanted in
the subcutaneous space utilizing a treatment (1200 ng/mL IL-10) perfusion fluid. 10x
magnification, white bar represents 100 µm.
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Immunohistochemistry showed there to be differences in the amount of macrophages and the
predominant phenotype present in the tissue surrounding the treatment probe as compared to the control
+

+

probe. The most significant differences were seen in macrophages staining CD68 and CD163 (Fig 16).
+

In the tissue surrounding the treatment (1200 ng/mL IL-10), more CD68 macrophages are seen as
+

compared to the tissue surrounding the control probe. Further, more CD163 [M(IL-10)] macrophages are
seen in the tissue surrounding the treatment probe as compared to the tissue surrounding the control
probes. Interestingly, when the tissue surrounding the 200 ng/mL treatment probes is compared to the
+

tissue surrounding the 1200 ng/mL treatment probes, a difference is seen in the amount of CD68 ,
+

+

+

CD206 , and CD163 macrophages. More macrophages (CD68 ) are seen in the 1200 ng/mL treatment
+

+

tissue as well as more M2 (CD206 ) and M(IL-10) (CD163 ) as compared to the 200 ng/mL treatment
tissue (Fig 17-19).
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Fig. 16. Macrophages surrounding the microdialysis probe. Left: These cells are preferentially
stained using antibodies specific for CD68. Right: These cells are preferentially stained using
antibodies specific for CD163. Top: Tissue surrounding a control microdialysis probe. Bottom:
Tissue surrounding a treatment (200 ng/mL IL-10) microdialysis probe. Images are 20X
magnification, paraffin embedded tissue.
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Fig. 17. Macrophages surrounding the microdialysis probe. These cells are preferentially stained
using antibodies specific for CD68. Top: 200 ng/mL IL-10 treatment tissue. Bottom: 1200 ng/mL
IL-10 treatment tissue. 20X magnification, paraffin embedded tissue.
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Fig. 18. M2 Macrophages surrounding the microdialysis probe. These cells are preferentially
stained using antibodies specific for CD206. Top: 200 ng/mL IL-10 treatment tissue. Bottom:
1200 ng/mL IL-10 treatment tissue. 20X magnification, paraffin embedded tissue.
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Fig. 19. M(IL-10) (M2c) macrophages surrounding the microdialysis probe. These cells are
preferentially stained using CD163. Top: 200 ng/mL IL-10 treatment tissue. Bottom: 1200
ng/mL IL-10 treatment tissue. 20X magnification, paraffin embedded tissue.
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3. Discussion

Any material which enters the body and is too large to be phagocytosed, results in the foreign
body response (FBR). The FBR results in the encapsulation of the material separating the material from
the rest of the body causing it to reside in its own microenvironment. This phenomena holds true for the
implantation of biomaterials as well. While the process of encapsulation and subsequent residing of the
biomaterial in a microenvironment has long been known to occur, it has been seen as an unfortunate yet
unavoidable consequence.
Macrophage activation (formerly macrophage polarization) is a process which plays a role in the
outcome of implanted biomaterials [12] and in fact has been shown to be an indicator of biomaterial
implantation outcome [13-15]. While much is known about how macrophages change activation state in
vitro little is known about the ability of macrophages to do so in vivo. Further, much of the in vivo work
has focused on using degradable biomaterials while there is very little to no information on the use of
non-degradable biomaterials in conjunction with modulators to shift the activation state of macrophages.
The ability to change and/or control the activation state of macrophages in vivo at an implant site might
result in better integration of the biomaterial into the surrounding tissue.
Microdialysis sampling technique is unique in its ability to simultaneously collect analytes from
and deliver modulators to the implant site. For this reason, microdialysis sampling technique is a useful
tool for investigating the effects of locally-delivered modulators on the biochemical processes at an
implant site. Coupling microdialysis sampling technique with histological analyses and
immunohistochemistry allows for the determination of whether a modulator is having advantageous
effects on fibrosis and shifting macrophages to a desired activation state, respectively.
Interleukin-10 was used in this study for a multitude of reasons. First, IL-10 is known to be an
activator of macrophages. It is known that IL-10 is capable of inducing a switch of macrophages to an
M2c [M(IL-10)] state which is characterized as being anti-inflammatory and pro-wound healing [16] and is
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known to play a role in limiting inflammatory responses [2, 17]. However, no studies have been
performed to determine the ability of IL-10 to induce M(IL-10) macrophages at a non-degradable implant
site. Second, while IL-10 is said to result in a pro-wound healing environment, it is unknown how the
subcutaneous space is affected by IL-10 during the FBR. Third, there are conflicting results on the
effects IL-10 has on the regulation of different cytokines such as CCL2 [4-6]. Knowing this information
will better illuminate the molecular mechanisms through which IL-10 is able to exert anti-inflammatory
effects and shift macrophage activation state.
In the first experiment, IL-10 (10 ng/mL) perfusion, the release of IL-10 from the microdialysis
probe resulted in a trend where CCL2 concentrations were higher in the dialysate collected from the
treatment probes as compared to the control probes. While a trend was seen, this trend was not
significant at the 95% confidence interval, only at a 90% confidence interval. While this is in
disagreement with studies which show IL-10 to inhibit CCL2 [18] it is not novel as reports show that IL-10
can cause an increase in CCL2 mRNA expression levels in a mouse lung fibrosis model where IL-10 was
over-expressed [19] and also in CCL2 protein concentrations [4]. Given that IL-10 seemed to cause an
increase in CCL2 concentrations, it was postulated that by increasing the amount of IL-10 delivered to the
implant site, a greater increase in IL-10 concentrations would be seen in treatment dialysates. This
increase in IL-10 concentration would thereby lead to a larger difference in CCL2 concentrations found in
treatment and control dialysates.
To deliver higher concentrations of IL-10 to the implant site, ultrafiltration was utilized where there
was a ~50% fluid loss (~30 µL/hour). Ultrafiltration is simply the loss of fluid across the microdialysis
membrane. While this phenomenon is generally seen as problematic in microdialysis sampling and
therefore avoided, it can be used to deliver higher concentrations of a modulator to an implant site. In the
IL-10 ultrafiltration experiment, the trend that was seen previously in the IL-10 (10 ng/mL) perfusion
disappeared and there was found to be no difference nor trend in the concentration of CCL2 found in the
dialysate from the treatment probe as compared to the control probe. To verify that this was due to
differential IL-10 effects on CCL2 and not due to analytes in the ECS possibly being diluted by the fluid
lost during ultrafiltration, IL-10 was delivered for four days (Four Day IL-10 Infusion). Again, no difference
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was seen in the concentration of CCL2 in the dialysate collected from the treatment probe as compared
to the control probe. Further, the concentrations of six other analytes (IL-1β, IL-6, IL-10, KC/GRO, MIP-2,
and RANTES) were tested and found to show no significant difference between treatment and control.
Since IL-10 is said to be anti-inflammatory and result in macrophages which produce a pro-tissue
remodeling, pro-wound healing state, histological analyses were performed to determine the effects IL-10
had on tissue. In the IL-10 (10ng/mL) perfusion, there was no appreciable difference seen in the H&E or
Masson's Trichrome stained tissue. While this may imply that IL-10 is not resulting in the antiinflammatory, pro-tissue remodeling, pro-wound healing state as expected, it may also be a result of
insufficient IL-10 being delivered to the wound site. It is important to note at this point that the relative
recovery of IL-10 through a CMA 20 100 kDa probe is ~1% (data not shown). This means that if 10
ng/mL IL-10 are being perfused through the microdialysis probe that only ~0.1 ng/mL of IL-10 is being
delivered to the wound site.
Firstly, ultrafiltration was used to increase the amount of IL-10 being delivered to the wound site.
When ultrafiltration was utilized, differences in cellular density as well as collagen formation were seen in
the treatment tissue as compared to the control tissue. The treatment tissue had less cellular density and
increased collagen surrounding the microdialysis probe. The decrease in cellular density would suggest
a decrease in inflammation at the implant site. On the contrary, the increase in collagen might suggest
reduced healing and scar tissue formation, especially given its organization. Again, it is not apparent
whether these findings are a result of the IL-10 being infused or from mechanical injury being sustained
from the fluid leaving the probe due to ultrafiltration. In the four day IL-10 infusion experiment, we find a
layer of densely packed cells immediately surrounding the treatment probe as well as more collagen
surrounding the treatment probe as compared to the control. Further, for the first time we see a large
extremely dense cellular area surrounding the treatment probe which is absent from the control tissue.
These results suggests that the IL-10 is not resulting in an anti-inflammatory, pro-tissue remodeling, prowound healing environment but rather is resulting in increased inflammation.
Given the anomalies seen in the IL-10 work thus far, a new hypothesis was derived with two
options: 1) IL-10 has very transient and dose dependent effects on tissue or 2) there is something
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entering the tissue abrogating the effects of IL-10 and resulting in an increase in inflammation. To
elucidate which issue was leading to the unexpected results, a series of experiments were performed to
determine if any components of the perfusion fluid were causing increased inflammation (Chapter 3).
What was found was that Dextran-70, a commonly used osmotic agent in microdialysis sampling
technique, is able to exit the probe resulting in increased inflammatory responses and even necrosis at
high concentrations.
Once Dextran-70 was identified as a pro-inflammatory agent and eliminated from the perfusion
fluid, experiments were performed where either 200 ng/mL or 1200 ng/mL IL-10 were infused. Similar
histological results were obtained from both 200 ng/mL and 1200 ng/mL IL-10 infusions. In the tissue
immediately surrounding the treatment probes, the same extremely dense cellular area was seen as was
seen in the four day IL-10 infusion only to a much greater extent. IL-10 has been shown to cause
apoptosis in monocytes [20, 21] which may lead to reduced clearance of apoptotic neutrophils and an
increase in apoptotic cells at the membrane/tissue interface resulting in the extremely dense cellular area
surrounding the probe. Once beyond this initial area, there is a decrease in cellularity which is not seen
in the tissue surrounding the control probe. In the 1200 ng/mL treated tissue, there is a tightly bound ring
of collagen which is parallel to the wound indicative of scar tissue formation [22, 23] with less collagen
seen beyond that as compared to the tissue surrounding the control probe. Interestingly, in the 200
ng/mL treated tissue, there is no sign of the scar tissue formation with very little collagen being seen
beyond the 'apoptotic/necrotic' area. This suggests that at 200 ng/mL, IL-10 has some anti-inflammatory,
pro-wound healing, pro-tissue remodeling effects. These effects might possibly be intensified if a lower
dose of IL-10 were used or if IL-10 were used in conjunction with a second modulator that would help
overcome the apoptotic effects.
The activation state of macrophages at an implant site has been shown to be a predictor of
implant outcome with early M2 predominance at the wound site leading to improved outcome as
compared to early M1 predominance at the wound site [15]. Further, Badylak's group has shown that a
scaffold wound site which is predominated by M2c macrophages results in improved integration and
outcome of the implanted scaffold [13, 14]. IL-10 has been reported to shift macrophages to the M(IL-10)
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phenotype (an M2c phenotype) [16, 24]. It is hypothesized that by delivering IL-10 to a wound site,
macrophages will shift to the M(IL-10) activation state resulting in improved integration of the biomaterial
with the host tissue and therefore increased longevity of the biomaterial. In this work, IL-10 was found to
have no effect on the predominant macrophage phenotype present at the wound site when delivered at
10 ng/mL regardless of whether the IL-10 was delivered for one day, ultrafiltrated, or delivered for four
consecutive days. However, at higher concentrations, 200 ng/mL and 1200 ng/mL, IL-10 was seen to be
able to cause a minimal shift in the activation state of macrophages surrounding the microdialysis probe
to an M(IL-10) state. It should be clearly noted at this point that different dextrans were used for 10
mg/mL studies and 200 ng/mL and 1200 ng/mL studies and the difference in dextran cannot be excluded
as a possible factor in the results. The shift in activation state was most evident in the 1200 ng/mL IL-10
infusion which would suggest that either this concentration is needed to deliver sufficient IL-10 to the
wound area to cause any effect or that the effects of the IL-10 on the activation state of macrophages is
dose dependant. Surprisingly, the histological results do not support this outcome but rather show
increased inflammation at the implant site in response to the higher concentrations of IL-10. This
anomaly may be due to the fact that IL-10 has been shown to cause apoptosis in macrophages [21].
Further, it can be expected that the predominance of M(IL-10) macrophages would be found close to the
microdialysis membrane as this is where the IL-10 is delivered and at the highest concentration. While
the microdialysis probe should cause a shift to a M2 phenotype on its own, if IL-10 is causing apoptosis in
M(IL-10) macrophages this might result in the remaining M2 macrophages present not being M(IL-10)
macrophages. Contrary to IL-10 and IL-10 macrophages which are considered pro-wound healing and
pro-tissue remodeling, M2 macrophages as a whole have been implicated in increased fibrosis in some
instances [25, 26]. This may in part explain the increased inflammation seen at the implant site in
response to high concentrations of IL-10.
At this point it should be explicitly noted that all the immunohistochemistry slides prepared were
formalin fixed paraffin embedded sections. Formalin fixed paraffin embedded sections are classically
used for histological analyses due to the high retention of tissue morphology. While this would also be
advantageous to immunohistochemical analyses, cross-linking becomes an issue as some epitopes
become blocked during the process. This requires that an antigen retrieval step be performed. Also, the
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paraffin must be removed from the tissue sections. Protocols have been established to perform
immunohistochemistry on formalin fixed, paraffin embedded tissue sections where an antigen retrieval
step and paraffin removal step are performed. Also, more antibodies are becoming available which are
capable of being used on formalin fixed, paraffin embedded tissue sections. While many in the field use
formalin fixed, paraffin embedded tissue sections for immunohistochemistry, we found that this technique
resulted in high background noise. Even though antigen retrieval and paraffin removal techniques were
used, we found there to be residual paraffin left on the tissue sections. When the tissue sections were
analyzed, we found that this residual paraffin fluoresced. This fact may in part explain why no differences
were seen in the immunohistochemistry in response to lower concentrations of IL-10 and why at high
concentrations of IL-10 very minimal differences were seen in the immunohistochemistry. Formalin fixed,
paraffin embedded tissue sections were abandoned for frozen sections in all remaining
immunohistochemistry analyses. Switching to frozen sections had two main advantages: 1) the high
amount of background noise seen with the paraffin was eliminated as there is no paraffin involved and the
frozen sections showed little to no background noise or non-specific binding of antibodies 2) a more
accurate profile of the macrophage activation state at the implant site could be obtained as monoclonal
antibodies can be used with the frozen sections which cannot be done with paraffin sections as the
antibodies are not available. It would be interesting and worth further investigation to use frozen sections
and determine if IL-10 is capable of causing a shift in the macrophage activation state at an implant site.

4. Conclusion

In this study microdialysis sampling probes were implanted in the subcutaneous space of male
Sprague Dawley rats. The microdialysis probe was used to locally deliver IL-10 to the wound site while
simultaneously collecting analytes from the ECS. Further, tissue histology, and immunohistochemistry
were performed to determine the effects of IL-10 on cellular density and collagen formation as well as
macrophage activation state, respectively. While IL-10 caused no alterations in the cytokine levels
tested, differences were seen in the tissue histology and macrophage activation state. The use of high
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levels of IL-10 resulted in increased inflammation at the wound site. However, high levels of IL-10 also
caused a minimal increase in the number of M(IL-10) macrophages at an implant site, though these
effects as well as any possible effects at lower levels might become more obvious through the use of
frozen tissue sections. While much work has been done to better understand macrophage activation, the
majority of this work has been performed in vitro with few in vivo studies being performed. It has been
postulated that through the use of modulators, which have been proven to shift macrophage activation
states in vitro, the activation state of macrophages can be altered or controlled resulting in improved
integration of biomaterials into the host tissue and increased longevity of these biomaterials. It is
important to understand how the use of these in vitro modulators correlates to in vivo responses. This is
the first study to investigate the ability of locally delivered IL-10 to alter macrophage activation state at an
implant site.
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MEMORANDUM

TO:

Julie Stenken

FROM:

Craig N. Coon, Chairman
Institutional Animal Care and Use Committee

DATE:

May 2, 2014

SUBJECT:

IACUC APPROVAL
Expiration date: May 11, 2017

The Institutional Animal Care and Use Committee (IACUC) has APPROVED protocol
14041: “Inducing and Monitoring Macrophage Polarization at an Implant Site in a Rat
Subcutaneous Model ” for the period of May 12, 2014 thru May 11, 2017

In granting its approval, the IACUC has approved only the protocol provided. Should there be
any further changes to the protocol during the research, please notify the IACUC in writing (via
the Modification form) prior to initiating the changes. If the study period is expected to extend
beyond May 11, 2017you must submit a new protocol. By policy the IACUC cannot approve a
study for more than 3 years at a time.
The IACUC appreciates your cooperation in complying with University and Federal guidelines for
involving animal subjects.

CNC/aem
cc: Animal Welfare Veterinarian
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